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ABSTRACT
The rapid emergence of bacteria that are resistant to today’s antibiotics makes
them more and more ineffective. Consequently, the need for a novel class of antibacterial
agents is rapidly increasing. The importance of this project is emphasized by the
emergence of several pathogenic bacterial strains that are resistant to all currently
available antibiotics on the market today. One way to approach this problem is to
develop drugs that target essential bacterial biosynthetic pathways. Based on bacterial
genetic information, the meso‐diaminopimelate (mDAP)/lysine biosynthetic pathway
offers several potential anti‐bacterial targets that have not been yet explored. One of
these, the dapE-encoded N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE)
catalyzes the hydrolysis of N-succinyl-L,L-diaminopimelate to L,L-diaminopimelate and
succinate. Since there are no similar pathways in mammals, inhibitors that target one or
more of the enzymes in the mDAP/lysine biosynthetic pathway will likely exhibit
selective toxicity against only bacteria.
It has been shown experimentally that deletion of the gene encoding for DapE is
lethal to Helicobacter pylori and Mycobacterium smegmatis. Therefore, DapEs are
crucial for bacterial cell growth and proliferation, making them potential targets for a new
class of antibiotics. Rational design of inhibitors for DapE relies on understanding the
active site structure and catalytic mechanism. Therefore, the DapE enzymes from
Haemophilus influenzae and Neisseria meningitidis were characterized biochemically and
xvi

crystallographically. In addition, residues situated within the active site were mutated
and the mutated enzymes were characterized via kinetic and crystallographic methods in
order to gain insight into substrate binding. In order to examine the role of the catalytic
domain of DapE truncated enzymes from Vibrio cholera and H. influenzae were
engineered by deleting their dimerization domains. And finally, a reliable and
reproducible spectrophotometric assay for DapE enzymes that is conducive to highthroughput screening was developed.

xvii

CHAPTER ONE
INTRODUCTION
Infectious diseases continue to be a serious threat to public health around the
world. Most importantly, the rapid emergence of resistant bacteria makes today’s
antibiotic’s more and more ineffective, consequently increasing the need for a novel class
of antibacterial agents.1 The Center for Disease Control and Prevention (CDC) recently
reported the emergence of several strains of Staphylococcus aureus that are resistant to
even the most powerful antibiotics of last resort, such as vancomycin. These data
emphasize the fact that no drug can prevent a simple staph infection from becoming
deadly.2 Just 12 years ago, vancomycin failed only ~0.3% of the time in treating
infections caused by Enterococcus faecalis, however this number increased 26-fold in
just four years.3 Various other strains of common bacterial species capable of causing
fatal illnesses (E. faecalis, Mycobacterium tuberculosis, Escherichia coli O157:H7, and
Pseudomonas aeruginosa) are already resistant to all existing drugs including
vancomycin and even to the newest antibiotic linezolid, which was first used in 1990.4,5
A summary of the commonly used antibiotics, their modes of action, and resistance
mechanisms is shown in Table 1.6
In the past, Streptococcus pneumoniae had been susceptible to penicillin, however
a new drug-resistant strain (DRSP) has recently emerged that is no longer vulnerable to
penicillin-type antibiotics.4 Recurrently, this type of resistance originates in clinical
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Table 1. Antibiotics in clinical use and modes of resistance.
Antibiotic
class

Example(s)

Target

Mode(s) of resistance

β-Lactams

Penicillins (ampicillin), cephalosporins
(cephamycin), penems (meropenem),
monobactams (aztreonam)

Peptidoglycan biosynthesis

Hydrolysis, efflux, altered target

Aminoglycosides

Gentamicin, streptomycin, spectinomycin

Translation

Phosphorylation, acetylation,
nucleotidylation, efflux, altered target

Glycopeptides

Vancomycin, teicoplanin

Peptidoglycan biosynthesis

Reprogramming peptidoglycan biosynthesis

Tetracyclines

Minocycline, tigecycline

Translation

Monooxygenation, efflux, altered target

Macrolides

Erythromycin, azithromicin

Translation

Lincosamides

Clindamycin

Translation

Hydrolysis, glycosylation, phosphorylation,
efflux, altered target
Nucleotidylation, efflux, altered target

Streptogramins

Synercid

Translation

C-O lyase (type B streptogramins),
acetylation (type A streptogramins),

Oxazolidinones

Linezolid

Translation

Efflux, altered target

Phenicols

Chloramphenicol

Translation

Acetylation, efflux, altered target

Quinolones

Ciprofloxacin

DNA replication

Acetylation, efflux, altered target

Pyrimidines

Trimethoprim

C1 metabolism

Efflux, altered target

Sulfonamides

Sulfamethoxazole

C1 metabolism

Efflux, altered target

Rifamycins

Rifampin

Transcription

ADP-ribosylation, efflux, altered target

Lipopeptides

Daptomycin

Cell membrane

Altered target

Cationic peptides

Colistin

Cell membrane

Altered target, efflux

2

3
environments where pathogenic and commensal bacteria are challenged with high
concentrations of antibiotics.7 Historically it has been shown that within hospital
settings, resistanat pathogens often emerge within a few years after a new antibiotic is
introduced (Figure 1).6 Pathogens that currently cause the majority of hospital infections
Figure 1. Antibiotic resistance evolution showing the rapid development of
resistance for several classes of antibiotics. The bars mark the time from the
introduction of an antibiotic to the clinic until the first clinical case of resistance to
that antibiotic was reported.8, 9, 10, 11
Eight years average
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and urgently require new drug candidates are: Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumonia, Acinetobacter baumanii, Pseudomonas aeruginosa, and
Enterobacter species (“ESKAPE” pathogens).12 Recently, Gram-negative
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Enterobacteriaceae, a bacterium that is resistant to carbapanem due to the New Delhi
metallo-β-lactamase-1 (NDM-1), made headlines as a major global health problem. In a
recent paper published by Kumarasami et al.,13 fourtyfour isolates were identified with
NDM-1 in India, Pakistan, and the UK. NDM-1 was mostly found among Escherichia
coli and Klabsiella pneumonia, which were highly resistant to all antibiotics except
tigecycline and colistin.13
The newest report from the CDC indicates that the number of estimated annual
illnesses and deaths caused by antibiotic resistance are 2,049,442 and 23,000,
respectively. The CDC has ranked antibiotic-resistant organisms based on seven criteria:
health impact, economic impact, rate of infection, ten-year projected rate of infection,
ease of spread, antibiotic availability, and prevention barriers. Number one in the CDC’s
most urgent category is Clostridium difficile, which causes 250,000 hospitalizations, at
least 14,000 deaths and $1 billion in healthcare costs each year. The other two organisms
are carbapenem-resistant Enterobacteriaceae (CRE) and drug-resistant Neisseria
gonorrhoeae. In March 2013, the CDC called CRE a "nightmare bacteria" being even
more dangerous than methicillin-resistant Staphylococcus aureus (MRSA). Among all of
the bacterial resistance problems, gram-negative pathogens such as Enterobacteriaceae,
Pseudomonas aeruginosa, and Acinetobacter are particularly dangerous due to becoming
resistant to nearly all antibiotics.14
Unfortunately, this pattern of resistance will persist as bacteria continue to
develop ways to survive. Resistance to antibiotics can be caused by four general
mechanisms: (a) inactivation or modification of the antibiotic; (b) alteration in the target
site of the antibiotic that reduces its binding capacity; (c) modification of metabolic

5
pathways to circumvent the antibiotic effect; and (d) reduced intracellular antibiotic
accumulation by decreasing permeability and/or increasing active efflux of the
antibiotic.15 Bacteria can develop resistance to antibiotics by mutating existing genes
(point mutations, deletions, inversions, insertions, etc.) or by acquiring new genes from
other strains or species (horizontal gene transfer).16
Despite the critical need for new antibiotics to treat drug-resistant infections the
number of new antibiotics approved by the Food and Drug Administration (FDA) has
declined 75 % over the last 24 years with only five new antibiotics approved in the last
few years and only three novel classes of antibiotics introduced within the last 40 years
(Figure 2).17 In a way, the antibiotic industry has been a victim of its own success. After
penicillin and other major antibiotics were discovered it was believed that the battle with
infectious diseases was conquered. Life expectancy increased and the number of deaths
caused by infectious diseases fell tremendously. Consequently, both grant funding and
research programs lead by pharmaceutical giants declined significantly.18 Many major
pharmaceutical and biotech companies left the antibiotic research field. For example,
since 1999, 10 of the 15 largest companies have significantly reduced or eliminated their
antibiotic research programs.19 One major reason why pharmaceutical companies are not
pursuing antibacterial research is simply due to low profit margins. Antibiotics are short
course therapies as opposed to billion dollar blockbuster drugs that typically treat chronic
diseases, such as high cholesterol. Moreover, the increased restrictions on the use of
antibiotics and more stringent regulatory requirements make antibiotic research even less
attractive.20 In addition, natural compounds such as penicillin have been very successful
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throughout the years and have provided the basic structures from which scientists have
made many analogues. Although this rout has been successful and potent compounds
Figure 2. Number of approved antibiotics between 1935 and 2007.

Number of approved Antibiotics
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such as amoxicillin have been discovered, no new classes of antibiotics have been
discovered and the number of modifications that can be introduced to a compound is
limited.20
Fortunately, congress together with other organizations finally recognized the
urgent need to encourage new antibiotic development. Policymakers are now offering
pharmaceutical companies patent extensions and tax breaks, in order to revive the interest
in antibiotic research. In November 2010, the Infectious Diseases Society of America
(IDSA) addressed the threat of antimicrobial resistance by insisting U.S. and European
Union leaders join forces in developing new antibiotics. To accomplish this goal, IDSA
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launched a new collaboration titled “10 x `20” initiative. The goal of this collaboration is
to create a joint venture that will develop 10 novel antibiotics by 2020.21 Governments
together with other nongovernmental organizations have made significant efforts to
increase the interest in antibiotic research. In the US, the federal Interagency Task Force
on Antimicrobial Resistance updated its “Public Health Action Plan to Combat
Antimicrobial Resistance” document in 2011.22 On June 12, 2012 Europe’s largest
public-private partnership between the European Commission and European Federation
of Pharmaceutical Industries and Associations (EFPIA) held a seminar devoted to the
clinical development aspects “Combating Antimicrobial Resistance – New Drugs 4 Bad
Bugs” (ND4BB). The Innovative Medicines Initiative was set up in 2008 to support
collaborative research between industrial and academic experts to reduce drug discovery
bottlenecks and boost pharmaceutical innovation within Europe.23 On June 26, 2012, the
U.S. Senate passed the FDA Safety and Innovation Act (FDASIA) which reauthorizes the
Prescription Drug User Fee Act (PDUFA) for the fifth time. The bill was mainly
designed to speed up reviews of novel drugs for infectious diseases as well as improve
communication between manufacturers and the FDA to prevent drug shortages. The
"Generating Antibiotic Incentives Now" act, which is a part of the PDUFA, was designed
to provide pharmaceutical and biotechnology companies with incentives to develop new
antibiotics for the treatment of life-threatening infectious diseases caused by drug
resistant pathogens. These pathogens primarily consists of resistant gram positive
pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin
resistant Staphylococcus and enterococcus, multi-drug resistant gram negative bacteria,
including Acinetobacter, Klebsiella, Pseudomonas and E. coli species, multi-drug
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resistant tuberculosis, and Clostridium difficile.

8
Moreover, it is extremely optimistic to

see both public and private organizations encouraging research and development by
combination of various incentives.
The area of genomics has influenced the discovery of novel antimicrobial agents
tremendously. It provided the ability to sequence entire bacterial genomes and identify
essential genes that upon deletion result in inhibition of cell growth. The main principle
lies in the fact that targets should not be shared with a human host and only be present in
the bacteria that are responsible for the disease. Libraries of compounds can now be
screened to find molecules that inhibit the enzymatic function of the target. Those
molecules can further be screened for antibacterial activity such as the ability to
successfully penetrate the cell membrane.25 As a result of these advances in genomics,
the meso-diaminopimelate (mDAP)/lysine biosynthetic pathway was validated as a viable
source of several potential antibacterial enzyme targets that have yet to be explored
(Figure 3).26 The initial steps in the pathway involve the four step conversion of aspartic
acid to L-tetrahydrodipicolinate. This compound can either be directly converted to
meso-DAP by the dehydrogenase pathway, acetylase pathway or the succinylase
pathway. Ultimately, all of these pathways lead to meso-DAP formation. However, the
succinylase pathway is the primary biosynthetic pathway in most Gram-negative and
Gram-positive bacteria for the synthesis of meso-DAP.27 The dehydrogenase pathway is
a high energy transformation and is limited to only few Bacillus species.27 The acetylase
pathway is also limited to only few Bacillus species.28
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Figure 3. Biosynthetic pathways of meso-diaminopimelic acid and lysine in bacteria.

The dapE-encoded N-succinyl-L,L diaminopimelic acid desuccinylase (DapE) is
a member of this meso-diaminopim elate (meso-DAP)/lysine biosynthetic pathway.27, 20,
23

Lysine, which is one of the products of the pathway, is an essential component in the

production of the peptidoglycan layer of Gram-positive bacterial cell walls.20 A second
product and an immediate precursor of lysine is the amino acid mDAP, which is used in
the peptidoglycan cell wall of Gram-negative bacteria, providing a link between
polysaccharide strands.29,2 Since there are no similar pathways in mammals, inhibitors of
DapE are hypothesized to provide selective toxicity against bacteria and show little or no
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toxicity towards humans. It has been shown experimentally that deletion of the gene
encoding for DapE is lethal to Helicobacter pylori and Mycobacterium smegmatis. Even
in lysine-supplemented medium H. pylori was unable to grow. Therefore, DapEs are
crucial for bacterial cell growth and proliferation.30, 31
DapEs catalyze the hydrolysis of N-succinyl-L,L-diaminopimelic acid (SDAP),
forming L,L-diaminopimelic acid and succinate (Figure 4).29 DapE is an ideal enzyme to

Figure 4. Reaction catalyzed by DapE.
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study in the mDAP/lysine biosynthetic pathway because it is highly soluble, readily
available in large amounts, and is capable of being genetically manipulated. Biochemical
studies revealed that the DapEs from E. coli and H. influenzae are small (approximately
42 kDa) dimeric enzymes that require two Zn(II) ions per mole of polypeptide for full
enzymatic activity.32 As-purified, DapE contains only one tightly bound Zn(II) ion and
exhibits approximately 80% of its total activity. DapE can be substituted with Co(II)
providing an enzyme that is twice as active as the native Zn(II) enzyme.33 It has also

11
2+

been shown by Broder and Miller that DapE can act as a Mn -activated Asp-specific
dipeptidase, by investigating the promiscuity of DapE upon substitution of the active site
zinc ions with different metals. Their study indicated that the metal content of DapE’s
active site regulates its role as an aspartate peptidase, which catalytically cleaves the
amide bonds of small dipeptide molecules with the general formula of Asp-X,
particularly Asp-Ser, Asp-Gly, Asp-Lue and Asp-Cys with exception of Asp-Pro. This is
possible due to the fact that the second metal binding site has a lower affinity for metal
ions as compared to the first metal biding site. Therefore, the authors propose that the
form of DapE that is active as a peptidase contains Zn2+ in the tight binding site and Mn2+
in the low-affinity site.34 Homology studies show that alignment of the gene sequences
of DapE with the aminopeptidase from Aeromonas proteolytica (AAP) and the
carboxypeptidase from Pseudomonas sp strains-RS-16 (CPG2) indicate that all of the
amino acids that function as metal ligands are highly conserved.29,35
Crystal Structure of DapE
One major limitation in understanding the catalytic mechanism and the design and
synthesis of inhibitors was the lack of an X-ray crystal structure of DapE enzyme. The
only crystal structure of DapE published until 2010 was an apo form of DapE from N.
meningitidis.36 Even though the crystal structure contributed key structural data, the lack
of active site metal ions made it difficult to determine the spatial arrangement of
catalytically relevant residues that reside within the active site. This hurdle was
overcome when Nocek, Gilner et al.37 reported the X-ray crystal structure of both the
mono- and dinuclear zinc DapE enzymes from H. influenzae and N. menigtididis. The
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architecture of the active site and the core of the catalytic domain of DapEs could now be
analyzed in more detail to gain insight on substrate binding and mechanism.
The X-ray crystal structures of the mono and dinuclear Zn(II)-forms of the DapE
from H. influenzae were solved at 2.0 and 2.3 Å resolution, respectively. These
structures closely resemble the DapE structure from N. meningitidis and as previously
published the enzyme is organized as a dimer with each monomer divided into two
domains: a larger catalytic domain, which forms a 3-layer (αβα) sandwich and a smaller
ferrodoxin-like domain that forms the dimer interface (Figure 5). The core of the
catalytic domain, which houses the active site supplies ligands for the zinc ions and
consists of an eight-stranded twisted β-sheets that are sandwiched between seven αhelices. The domains are connected via a small hinge region that allows movements of
the dimerization domain in reference to the catalytic domain. The shape of the DapE
homodimer resembles twisted rotary style telephone receiver with the catalytic domain
located on the outside edge and separated by ~47 Å. The active site cleft is located in the
center of the catalytic domain and is constituted by residues from five loops. 37
Obtaining the monozinc form of the DapE enzyme allowed confirmation of
previously published kinetic and spectroscopic results, which showed that DapE
maintains activity with only one metal ion in the active site. It also allowed confirmation
of the assignment of the first metal binding site. In the active site of [Zn_(DapE)], Zn1
resides in a distorted tetrahedral geometry coordinated by the carboxylate oxygens of
D100 and of E163 as well as one nitrogen atom of H67 (Figure 6). The second
coordination site is filled by an oxygen atom provided from a water molecule.
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Figure 5. Ribbon drawing of dinuclear DapE from H. influenzae.

In [ZnZn(DapE)], the active site contains two Zn(II) ions at a distance of 3.36 Å apart
(Figure 7). Each of the Zn(II) ions adopt a distorted tetrahedral geometry and are
coordinated by one imidazole group (H67 for Zn1 and H349 for Zn2) and one
carboxylate group (E163 for Zn1 and E135 for Zn2). Both Zn(II) ions are bridged by an
additional carboxylate groups of D100 on one side and water/hydroxide on the opposite
side, forming a (μ‐aquo)(μ‐carboxylato)dizinc(II) core with one terminal carboxylate and
one histidine residue at each metal site. These structures confirm previous data
suggesting that H67 and H349 are active site ligands.32, 38 The structure also confirmed
that the position of glutamate E134 indicates its important role in the catalysis,
functioning as a general acid/base, previously reported by Davis et al.38
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Figure 6. Active site of [Zn_(DapE)] from H. influenzae.

Figure 7. Active site of [ZnZn(DapE)] from H. influenzae.
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Analysis of the molecular surface of DapE together with its X-ray crystal
structures, revealed a negatively charged cavity that extends along the catalytic domain.
(Figure 8). It is postulated that the substrate binds in an extended conformation, lining
Figure 8. Surface rendering of [ZnZn(DapE)] showing the charge distribution and
depicting the smile‐shaped active site cavity. Blue: positive charge; Red: negative charge.

up along the grove with the peptide bond positioned over the active site metals. Substrate
binding is further stabilized by interactions between substrate carboxylic groups with
positively charged amino acid side chains. The potential positive charged residues that
could possibly play this role are K175, K178, and N345 at one end and R258, R329, and
K139 at the opposite end (Figure 9). The side chain of K135 is ~6 Å away from the
center of the active site, which allows for an interaction of amino group of lysine with the
carboxylate group of substrate and thus, be involved in recognition and stabilization of
substrate at the active site. On the opposite side, the carboxyl group of L,L‐ SDAP could
be stabilized by an interaction with R258 and R329. T325, which is centrally positioned
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Figure 9. Side chains potentially involved in binding and substrate stabilization.

on a loop overhanging the active site, is also in hydrogen bond distance (3.11 Å) of the
carboxyl group of the L,L‐ SDAP moiety.
The architecture of the active site and the core of the catalytic domain of HiDapE
are strikingly similar to AAP and CPG2, even though they catalyze markedly different
hydrolytic reactions.39,40 These structures provide an important starting point for
mechanistic studies as well as the design of novel inhibitors for DapE enzymes.
Proposed Mechanism of DapE
Based on the X-ray crystal structure, previously reported kinetic and
spectroscopic studies of DapE and the recently published mechanisms of AAP41, 41b a
refined catalytic mechanism for DapE was proposed (Figure 10).37 After recognition of
the L,L-SDAP the peptide carbonyl oxygen of L,L-SDAP coordinates to Zn1, expanding
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its coordination number from four to five and activating towards nucleophilic attack.
Once the zinc-bound hydroxide is formed, it can attack the activated carbonyl carbon of
the substrate, forming an η-1-μ-transition-state complex.33 E134 provides a proton to the
penultimate amino nitrogen of SDAP, which facilitates product release. Once the
products are released, a water molecule bridging the two metal ions is replaced. In the
absence of a second metal ion, H349 is in position to assist in orienting the substrate
properly in the active site through the formation of a hydrogen bond with a carboxylate
side chain of the substrate, thereby stabilizing the transition-state intermediate. In the
presence of a dinuclear site the second metal ion likely coordinates either the peptide
carbonyl oxygen in a bridging fashion or a carboxylate side chain of the substrate.
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Figure 10. Proposed mechanism of DapE (a) monozinc DapE and (b) dizinc DapE.
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Potential Inhibitors of DapE
Several compounds containing zinc-binding groups (ZBG’s) including thiols,
carboxylic acids, boronic acids, phosphonates and hydroxamates have been screened
delivering a number of micromolar inhibitors of DapE from H. influenzae. Thus far, the
most potent inhibitors include L‐captopril (IC50 = 3.3 μM, Ki = 1.8 μM), L‐penicillamine
(IC50 = 13.7 μM , Ki = 4.6 μM), 2‐thiopheneboronic acid (TPhB) (IC50 = 92 μM, Ki = 67
μM) and phenyl boronic acid (PhB) (IC50 = 107 μM, Ki = 56.9 μM).42 Particularly
interesting is the fact that DapE is stereoselective with respect to recognition of
inhibitors. D‐penicillamine and D‐captopril are weaker inhibitors than the corresponding
L‐isoform. Since crystallization attempts for DapE from H. influenzae in the presence of
L‐captopril, L‐penicillamine, 2‐thiopheneboronic acid or phenyl boronic acid have been
unsuccessful, an orthologous crystallization approach has been undertaken as
homologous proteins have different propensities for crystallization. While the aminoacid sequences of homologues indicate a similar fold, there may be subtle differences so
crystallization can occur under alternative conditions providing inhibited structures.43 By
pursuing this goal the chances of obtaining structures with inhibitors bound to the active
site will increase. The other advantage of this approach is that a broader spectrum of
DapE targets can be analyzed, which will provide additional structural insight to
understand the mechanism of the DapE enzyme family. Ultimately we were able solve
crystal structures of mono and di-zinc forms of DapE from N. meningitidis utilizing this
approach, which will provide insight for the rational design of highly‐selective inhibitors
of DapE.
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Conclusion
The importance of this project is accentuated by the increasing rate of antibiotic
resistant bacteria, which has escalade to become a worldwide crisis. The research
presented in this dissertation provides insight into substrate-binding as well as the
mechanism of DapE, which has been identified as a potential antimicrobial target.
Moreover, the information elucidated from the experimental data shine light onto the
binding of inhibitors and provides important information required for the design of
inhibitors of DapE enzymes. Rational design of inhibitors relies on understanding the
active site structure and catalytic mechanism. Therefore, the DapE enzymes from H.
influenzae and N. meningitidis were characterized biochemically and crystallographically.
In addition, residues situated within the active site were mutated and characterized via
kinetic and crystallographic methods to gain insight into substrate binding. In order to
examine the role of the catalytic domain of DapE truncated enzymes from Vibrio cholera
and H. influenzae were engineered by deleting their dimerization domains. Moreover,
inhibition of DapE with L-captopril was investigated using several spectroscopic as well
as crystallographic techniques, which produced the first inhibited structure of DapE.
More importantly, the research has identified a viable assay for High Throughput
Screening of Inhibitors, which allows for testing of a large number of inhibitors in a short
period of time. This approach has allowed five new potential inhibitor of DapE to be
identified, that can be used as synthons for future design of potent inhibitors. This work
has provided information that could benefit the healthcare and the general wellbeing of
society given that multidrug resistant bacteria pose a serious and increasing threat to
human health.

CHAPTER TWO
THE ROLE OF THE DIMERIZATION DOMAIN AND THE ACTIVE SITE
LOOP IN DAPE ENZYMES
Introduction
Emerging antibiotic resistance has been recognized as a world-wide health issue
since the introduction of penicillin more than 80 years ago.4, 44 Most importantly, the
rapid emergence of resistant bacteria makes today’s antibiotics more and more
ineffective, consequently increasing the need for a novel class of antibacterial agents.45
Currently available antibiotics target only a limited number of microbial pathways and
employ two major strategies: (i) inhibition of cell wall remodeling and (ii) inhibition of
protein synthesis.46 As a result, only two new classes of antibacterial drugs have reached
the market since 1962.47, 48, 49 The Center for Disease Control and Prevention (CDC)
recently reported the emergence of several strains of Staphylococcus aureus that are
resistant to even the most powerful antibiotic of last resort, vancomycin. These cases
emphasize the fact that no drug can prevent a simple staph infection from becoming
deadly.50 According to the Infectious Diseases Society of America (IDSA), a minimum of
ten new systemic antibacterial drugs need to enter the market by the year 2020 in order to
maintain proper control of infectious diseases. Therefore development of new classes of
inhibitors that target essential metabolic pathways and unique enzymes is critical in order
to maintain control of infectious diseases.21, 51
21
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The lysine biosynthetic pathway offers several enzymes that could serve as
potential drug targets. 52, 53, 54 Two products of this pathway, lysine and mesodiaminopimelate (mDAP), are essential for protein and peptidoglycan cell wall synthesis
in Gram-negative and most Gram-positive bacteria. Many bacteria, plants and algae
synthesize lysine and meso-diaminopimelic acid (mDAP) from succinic acid.27-28, 53 In
contrast, lysine is not synthesized in humans but it is an essential amino acid, therefore it
must be ingested. It has been shown that deletion of the dapE gene in the mDAP/lysine
biosynthetic pathway that encodes the N-succinyl-L,L-diaminopimelic acid desuccinylase
(DapE) is lethal in Helicobacter pylori and Mycobacterium smegmatis.55 DapE
hydrolyzes N-succinyl-L,L-diaminopimelic acid to L,L-diaminopimelic acid and
succinate.53 DapE is a part of a biosynthetic pathway that is the major source of lysine in
bacteria, and is essential for cell growth and proliferation. Since there are no similar
biosynthetic pathways in mammals, inhibitors that target DapEs are hypothesized to
exhibit selective toxicity against bacteria and have little or no effect on humans.27 DapE
coding genes have been identified in all pathogenic Gram-negative bacteria, and the
enzyme has been purified and characterized from several sources.55a, 55b, 56, 57, 58, 59 Of
particular interest are DapEs from the “ESKAPE” pathogens, which are responsible for
an increasing number of the antibiotic resistant nosocomial infections in the United
States.60 Alignment of the DapE gene from Haemophilus influenzae (HiDapE) with the
gene sequences of DapEs from “ESKAPE” pathogens reveals at least 49% identity.61
All the DapE enzymes characterized to date belong to the M20 family of
dinuclear Zn(II)-dependent metalloproteases. Structural studies of M20 metalloproteases
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showed that these enzymes exist as dimers comprised of catalytic and dimerization
domains or monomers having a single catalytic domain.62 Structural studies on HiDapE
revealed that the enzyme belongs to the former group composed of a larger thioredoxinlike 3-layer (αβα) sandwich domain that carries out catalysis and a smaller ferrodoxinlike domain providing the dimer interface. The core of the catalytic domain consists of an
eight-stranded twisted β-sheet that is sandwiched between seven α-helices and houses the
active site. The active site is constituted by residues from five loops, contains two zinc
ions, and is exposed to the solvent.63
The architecture of the active site of HiDapE and the core of the catalytic domain
are strikingly similar to the aminopeptidase from Aeromonas proteolytica (AAP) and the
carboxypeptidase from Pseudomonas sp strain-RS-16 (CPG2) 64, even though they
catalyze markedly different hydrolytic reactions. One explanation for this similarity is
the highly flexible design of their active sites, which are constructed by five loops. This
design preserves the dinuclear catalytic core and at the same time allows for evolution of
specificity for a new substrate without the need for major modifications to the overall
structure. The flexibility of the active site is especially relevant from the perspective of
understanding substrate recognition and binding which is directly related to inhibitor
design. In order to examine the role of the catalytic domain of DapE enzymes and the
role of the active site loops, we have engineered the HiDapE and the DapE from Vibrio
cholerae (VcDapE) by deleting their dimerization domains. This truncation leads to
protein constructs that have only the catalytic domain, are monomeric in solution, and
closely resemble AAP. Kinetic characterization of the truncated DapEs (VcDapET and
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HiDapE ) shows that the activity of catalytic domain is not detectable under standard
assay conditions. X-ray crystallographic data and molecular dynamic simulations along
with site-directed mutagenesis studies provide insight into the role of the dimerization
domain and emphasize the importance of the active site loops in catalysis.
Materials and Methods
Gene cloning and protein expression—The coding genes of full-length VcDapE
and HiDapE that were cloned in vector pMCSG7 were amplified by PCR from V.
cholerae O1 biovar El Tor str. N16961 (ATCC) and from H. influenzae strain (ATCC)
respectively with KOD DNA polymerase using conditions and reagents according to the
standard protocol described previously.65 The truncated version of HiDapET (residues
181-294 deleted) and VcDapET (residues 181-295 deleted) were designed based on the
full-length HiDapE structure and were cloned using the same procedure. These deletion
proteins were reengineered in such a way that the C-terminal domain was truncated at the
connector region between the dimerization and the catalytic domains and replaced with a
GG linker. The deletion of the region coding for the dimerization domain was achieved
via PCR of pMCSG7-VcDapE and pMCSG7-HiDapE according to the previously
described protocol.66 The following primers were used: VcDapET 181-295;
5’TGGCGGTGGCTTCCTGACCGATACGGGCGA3’and
5’GGAAGCCACCGCCACGACGGCCATTTTTCACC3’, HiDapET 181294;5’CGGCGGTGGCTTTTTAACAAAACCAGGTAAATTATTAGATTCGATAACC
3’ and 5’AAAAAGCCACC GCCGCGGCGACCATTTTTGAC3’. This process
generated expression clones of fusion proteins that have the N-terminal His6-tag followed
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by a TEV protease recognition site (ENLYFQ↓S) followed by the DapE catalytic
domain. All proteins were expressed in an E. coli BL21(DE3)-derivative that harbors the
pMAGIC plasmid encoding one rare E. coli Arg tRNA (covering codons AGG/AGA).
The transformed BL21(DE3) cells were grown at 37 °C in LB medium and protein
expression was induced with 1 mM isopropyl-β-d-thiogalactoside (IPTG). The cells were
then incubated and shaken vigorously at 18 °C overnight. The harvested cells were resuspended in lysis buffer (500 mM NaCl, 5% (v/v) glycerol, 50 mM HEPES, pH 8.0, 10
mM imidazole, 10 mM 2-mercaptoethanol) and stored at −80 °C.
Purification of VcDapE, VcDapET and HiDapET—The VcDapE, VcDapET and
HiDapET proteins were purified according to the standard Ni-NTA affinity
chromatography protocol described previously.65 The 6-His tag was removed by treating
each enzyme with TEV protease for 16 h at 4 °C in 50 mM HEPES, pH 7.5. Cleaved
protein was separated from TEV using Ni-NTA affinity chromatography. After Ni-NTA
column chromatography, VcDapET and HiDapET were further purified by size-exclusion
chromatography on a HiLoad 16/600 Superdex 200 Prep Grade (GE Healthcare) using
standard crystallization buffer (250 mM NaCl, 20 mM HEPES pH 7.5, and 1 mM TCEP)
and concentrated to 25 mg/ml. The full-length VcDapE protein was purified according to
the same procedure however the size-exclusion chromatography step revealed formation
of “soluble aggregates”. Therefore, the buffer conditions were altered such that the salt
concentration was increased to 800 mM NaCl and glycerol (10%) was added, allowing for
purification of a small quantity of soluble protein.
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Determination of Molecular Weight of VcDapE, VcDapE and HiDapE —The
molecular weight (MW) of HiDapE, HiDapET and VcDapET proteins in solution at
concentration of 5 mg/ml was evaluated by size-exclusion chromatography (SEC) on a
HiLoad 16/600 Superdex 200 Prep Grade column (GE Healthcare) in the crystallization
buffer. The column was calibrated with aprotinin (6.5 kDa), ribonuclease A (13.7 kDa),
carbonic anhydrase (29 kDa), ovalbumin (43 kDa), conalbumin (75 kDa), aldolase (158
kDa), ferritin (440 kDa), and thyroglobulin (669 kDa) as standards. The calibration curve
of Kav versus log MW was prepared by using the equation Kav=Ve–Vo/Vt–Vo, where
Ve=elution volume for the protein, Vo = column void volume, andVt=total bed volume
(Figure 11).
Figure 11. Analysis of the oligomeric state by size exclusion chromatograpy.
Chromatogram showing elution of three DapE proteins (WT-HiDapE (blue), HiDapET
(red), VcDapET(green)) from the calibrated column. The inset shows the calibration
curve obtained by plotting Kav versus logMW forthe following standard proteins:
Aprotinin (6.5 kDa, I), ribonuclease A (13.7 kDa, II), carbonic anhydrase (29 kDa, III)
ovalbumin (43 kDa, IV), conalbumin (75 kDa, V), aldolase (158 kDa, VI), ferritin (440
kDa, VII), and thyroglobulin (669 kDa, VIII).
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Kinetic characterization of VcDapE, VcDapE , and HiDapE —Recombinant WTVcDapE, VcDapET, and HiDapET were characterized biochemically by monitoring amide
bond cleavage of L,L-SDAP at 225 nm ( = 698 M-1 cm-1). The assay was performed in
triplicate in 50 mM phosphate buffer, pH 7.5, in the presence of two equivalents of Zn(II).
Enzyme activities were expressed as units/mg where one unit is defined as the amount of
enzyme that releases 1 µmol of L,L-SDAP at 25 °C in 1 min. Km and kcat values were
obtained by fitting initial rates data to the Michaelis-Menten equation using Origin
software.59, 67 Catalytic activities were determined with an error of ± 10%.
Protein crystallization—The sitting-drop vapor-diffusion method was used to
obtain crystals of VcDapET and HiDapET at 16 °C using a Mosquito liquid handling robot
with 96 well plates. Crystals of both the apo- and dinuclear Zn(II)-loaded forms of
VcDapET were obtained using 400 nl of a precipitant solution (20% (v/v) 1,4-butanediol,
0.1 M sodium acetate pH 4.5) and 400 nl of a 19 mg/ml solution of VcDapET in
crystallization buffer within 14 days. In order to grow the crystals of dinuclear Zn(II)loaded forms of VcDapET 1mM ZnCl2 solution was added to the protein solution.
Crystals of HiDapET were obtained using 400 nl of a precipitant solution (0.2 M
ammonium acetate, 0.1 M BIS-TRIS pH 5.5, 25% (w/v) polyethylene glycol 3350) and
400 nl of a 15 mg/ml solution of HiDapET within two weeks. The asymmetric unit
contains two monomeric molecules of the HiDapET. For cryoprotection, all crystals were
transferred to, the mother liquid containing 25% mixture of glycerol and ethylene glycol.
Data collection and structure determination—Prior to data collection, the X-ray
florescence spectrum was recorded for VcDapET, HiDapET and apo-VcDapET crystals,
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which identified the presence of Zn ions in the protein crystals of VcDapE and HiDapET.
T

Data collection was carried out on the 19-ID beam line of the Structural Biology Center
at the Advanced Photon Source according to procedures described previously.63 Data
were collected at a wavelength of 0.98 Å from the single crystals and were processed
using HKL3000. Crystallographic parameters are summarized in Table 2. Initially data
for both VcDapET were processed, scaled and structures were refined in the space group
P3212. Even though models refined to low R-factor (Rcryst/Rfree= ~16/18%), the spurious
density features were observed in the electron density maps. Re-examination of the data
and twinning test performed using Xtriage in Phenix 68 indicated a perfect twinning with
the twinning operator parallel to two-fold axis making it pseudo P3212. Therefore data
were rescaled in the space group P32. The structures of VcDapET and HiDapET were
determined by molecular replacement using the catalytic domain of HiDapE (PDB ID
3IC1) as a search model.63 Molecular replacement searches were completed using
MOLREP of the CCP4 suite.69 The initial models were rebuilt manually and refined
using programs REFMAC 5.5 70 and Phenix.68 The final models were refined against all
reflections except for 5% randomly selected reflections, which were used for
monitoring Rfree. The final rounds of refinement were carried out using TLS refinement
with 5 TLS groups. The final refinement statistics for all structures are presented in
Table 2. Analysis and validation of the structures were performed with the aid of
MOLPROBITY and COOT validation tools. Figures were prepared using program
Pymol.
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Table 2. Data and Refinement Statistics for VcDapE -apo, VcDapE -ZnZn and HiDapETZnZn.
VcDapET-apo VcDapET-ZnZn HiDapET-ZnZn
Data collection statistics
T

Space group
Unit cell (Å)

P32
a = 49.6,
b =49.6,
c = 232.6

T

P32
a = 49.9,
b =49.9,
c = 231.8

P21
a = 61.7,
b = 44.7,
c = 92.5,
o

Resolution (Å)
Wavelength (Å)
Number of observed reflections
Number of unique reflections
Redundancy b
Rmergea,b (%)
Rrim a,b (%)
Rpim a,b (%)
Completenessb (%)
I/σ
Phasing
phasing method
Refinement statistics
Rcryst (%)
Rfree (%)
protein residues
zinc ion/acetate/butanediol/
glycerol/ethanediol/
solvent
Rmsd from target values
bond lengths (Å)
bond angles (deg)
Average B factors (Å2)
protein
Zn
H2O

37.6-1.65
0.98 Å
523779
77006
6.8 (3.8)
5.9 (50.1)
6.4 (56.7)
2.4 (25.8)
99.6 (93.8)
40 (2.3)

40-1.65
0.98
299329
70716
4.2(1.8)
5.1 (26.0)
5.8 (35.5)
2.6 (23.1)
91.3 (49.2)
23.2 (2.1)

30-1.84
0.98
99336
42453
2.3(2.2)
9.2 (55.7)
10.5(82.6)
6.5(51.0)
96.5 (97.8)
9.5 (2.1)

MR

MR

MR

13.81
17.13
532
-/1/6/2/4

14.32
16.59
513
2/-/6/3/3

19.7
24.9
505
4/-/-/-/-

541

541

284

0.020
2.11

0.020
1.43

0.021
2.03

14.78
28.10

14.77
13.93
24.19

27.7
26.1
38.7

PDB ID

4ONW

4OP4

4H2K

Ramachandran (%)c M.F./A.A.

97.5/2.5

97.3/2.7

96.8/3.0

a

Rmerge = ΣhklΣi|Ii(hkl) − Ihkl|/ΣhklΣiIi(hkl), where Ii(hkl) is the ith observation of reflection hkl, and〈Ihkl〉is the
weighted average intensity for all observations i of reflection hkl.
Rrim = Σhkl(N/(N − 1)1/2)Σi|Ii(hkl) − h l|/ΣhklΣiIi(hkl), and Rpim = Σhkl(1/(N − 1)1/2)Σi|Ii(hkl) − h l|/ΣhklΣiIi(hkl).
b
Numbers in parentheses are values for the highest-resolution bin.
c
As defined by MOLPROBITY (M.F. –the most favored/ A.A additionally allowed)
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Protein Data Bank accession code—The atomic coordinates and structure factor
file for the structure of the catalytic domain of apo-VcDapET, ZnZn-VcDapET and ZnZnHiDapET have been deposited in the RCSB Protein Bank with accession code 4ONW,
4OP4 and 4H2K, respectively.
Molecular modeling and dynamics simulations—The structure of the catalytic
domain of VcDapET is well ordered and excellent electron density is observed for protein
main-chain, side-chains, metal, phosphate ions, and water molecules. Using the VMD
molecular graphics program 71, the protein model with its hydrogen atoms was created
and placed in a water-box containing 7826 TIP3 water molecules 72, 13 sodium, and 2
chloride ions to neutralize the charge and provide counter ions. The charges on the
histidine residues were determined by inspection of their local environments. The energy
of this initial structure was minimized with 3,000 steps of conjugated gradient
minimization using the CHARMM27 force field 73 and the NAMD molecular dynamics
(MD) program.74 The structure was relaxed by gradually heating it from 10 to 310 K in
steps of 10 K with 1,000 steps of molecular dynamics at each temperature. Periodic
boundary conditions were used. The cutoffs for non-bonding (van der Waals and
electrostatic) interactions were 12 Å. The switch distance was 10 and 1.0 Å using a 1–4
scaling factor. The time step was 2 fs. These conditions were used for all of the
molecular dynamics simulations. After 10,000 steps of pressure and temperature
equilibration using a Langevin piston, the system was subjected to 30,000 steps of
molecular dynamics. This process constitutes equilibration of the structure. The
structures for HiDapET and HiDapE were also equilibrated in the same manner. Since
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these X-ray structure models had a few loops missing due to the poor electron density
maps, the missing regions were modeled using the modeling tools found in Swiss PDB
Viewer.75 The complete VcDapE structure was produced through homology modeling,
using HiDapE as a template through the automated mode of the Swiss Model service.76
The two chains of VcDapE were produced separately from each other, combined using
VMD, and equilibrated in the manner previously described. The X-ray structure for AAP
(PDB ID 1RTQ) 64b was used as a standard for comparison as AAP and dinuclear Zn(II)loaded VcDapET and HiDapET are characterized by similar active sites and sequence
lengths. For each of these five structures, 5 ns of simulation data were accumulated. The
rmsd per residue values were calculated for MD production runs of the four structures
using the VMD molecular graphics program.71 These calculations were used to
determine structural changes between each of the five structures. MOLMOLplots 77 were
also generated for each structure to give a visual depiction of the structural changes,
especially for areas of large movement. For these diagrams 171 equally spaced snapshots
over a 5 ns simulation were used for each of the five proteins. Three of the simulations
(ZnZn(VcDapET), HiDapET and HiDapE) were run for 10 ns, but there were no
significant differences in the flexibilities of these when the second 5 ns were compared
with the first 5 ns. All of the MOLMOL plots (Fig 13 and 14) used only the first 5 ns of
data so that they are directly comparable.
Loop V Site Directed Mutagenesis—The site-directed mutants T325A, T325S and
T325C of WT-HiDapE were prepared using the Quick Change Site-Directed Mutagenesis
Kit (Stratagene) following the procedure outlined by Stratagene using the following
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primers, T325A: 5’-ACAGGTGGCGGCGCGTCAGACGGTC-3’, 5’GACCGTCTGACGCGCCGCCACCTGT-3’, T325S: 5’ACAGGTGGCGGCTCGTCAGACGGTC-3’, 5’GACCGTCTGACGAGCCGCCACCTGT-3’, T325C: 5’GCTGAAACAGGTGGCGGCTGCTCAGACGGTCGTTTTATT-3’, 5’AATAAAACGACCGTCTGAGCAGCCGCCACCTGTTTCAGC-3’. Polymerase Chain
Reaction (PCR) was performed using 70 ng of a dsDNA template. PCR was performed
at 95 °C for 30 seconds followed by 16 cycles of (95 °C for 30 seconds, 55 °C for 1
minute, 68 °C for 5 minutes) and final extension at 68 °C for 6 minutes. Reaction
products were transformed into BL21(DE3)/magic E. coli competent cells (Invitrogen)
and grown on Luria-Bertani agarose plates containing ampicillin (100 µg mL-1) and
kanamycin (25 µg mL-1). A single colony of each mutant was grown in 5 mL LuriaBertani medium containing ampicillin (100 µg mL-1) and kanamycin (25 µg mL-1).
Plasmids were isolated using the QIAprep-Spin Miniprep Kit (QIAGEN). The plasmid
DNA was sent to the DNA sequencing facility (University of Chicago Cancer Research
Center DNA Sequencing Facility, Chicago IL) to confirm the mutations. Glycerol stocks
were prepared and stored at -80 °C until further needed. Purification of HiDapE T325A,
T325C and T325S mutant enzymes and kinetic characterization was conducted as
described above.
Circular Dichroism (CD) Spectroscopy— The secondary structure of WT DapE
and T325 mutants were measured using Olis DSM 20 circular dichrometer. Data was
collected at room temperature with constant nitrogen flow every 1 nm, in the wavelength
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range of 190 - 260 nm. All samples were measured in a cylindrical quartz cuvette with a
1 mm pathlength in 10 mM phosphate buffer pH 7.0. Three repetitive scans were
averaged, smoothed and background-subtracted for each measurement. Millidegree
values obtained were converted to molar ellipticity (deg·cm2·dmol-1) by using the
equation: Molar ellipticity = moM/10×L×C, where mo is millidegrees, M is molecular
weight (g/mol), L is path length of cuvette (cm) and C is concentration (g/L). CD data
from 190 to 260 nm were also analyzed to estimate the secondary structure composition
of Wild type and the mutants using the CDSSTR program in Dichroweb.78
Results
Kinetic characterization of wild type and truncated DapE—Kinetic data were
obtained for recombinant VcDapE, HiDapE, VcDapET, and HiDapET by monitoring
amide bond cleavage of L,L-SDAP at 225 nm. The kcat value obtained for WT-VcDapE
was 80 ± 10 s-1 with a corresponding Km value of 1.2 ± 0.2 mM while the kcat value
obtained for HiDapE was 114 ± 10 s-1 with a Km value of 0.8 ± 0.1 mM, which is in good
agreement with previous studies.67b Surprisingly, no detectable activity was observed for
HiDapET or VcDapET under the standard assay conditions.
Structure of the catalytic domain of HiDapET—Deletion of the dimerization
domain led to a monomeric structure for HiDapET. The monomeric nature of HiDapET in
solution was corroborated by size exclusion chromatography (SEC) The SEC analysis
confirmed a weight (MW) of 28.4 kDa (the theoretical mass of a monomer is 28.9 kDa,
while the wild-type dimer’s theoretical mass is 82.6 Da) (Figure 11). The structure of
HiDapET was determined and refined at 1.84 Å resolution and the final model shows two
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independent monomers in the asymmetric unit. The structure of the catalytic domain is
virtually identical to the catalytic domain of full-length HiDapE (PDB ID 3IC1) (Figure
12A, B, & C).63 Both structures overlay closely with rmsd for Cα atoms of 0.65 Å over
254 residues. Two zinc atoms were found in the active site and reside in the same
position as in dimeric structure of WT-HiDapE separated by 3.40 Å. Superimposition of
the active site regions shows nearly identical conformations of main chain and side
chains with rmsd as low as 0.15 Å for the metal ions and side chains of residues involved
in their coordination (Figure 12C). Therefore the structure of the catalytic core of the
enzyme is extremely well preserved. Larger differences within the active site area are
observed in two regions containing solvent exposed loops. Region I (residues 176-187)
has been engineered to replace what was originally the connector/hinge region formed by
two loops linking the catalytic domain with the dimerizaton domain (Figure 12C, Region
I). This region is highly flexible and is disordered in the crystal structure of HiDapET
(with no electron density observed for residues 182-187). Region II (residues 209-224),
which corresponds to a loop overhanging the active site metal ions (loop V, vide infra)
adopts a different conformation in comparison to that observed in the HiDapE structure
(rmsd of 1.5 Å between the structures). Two residues within loop V (Gly21 and Gly212)
are disordered in the structure of HiDapET (Figure 12C).
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Figure 12. X-ray Crystal Structures of WT-HiDapE and HiDapE . (A) Dimer
architecture based on the structure of WT-HiDapE. (B) Close-up view of the catalytic
domain of WT-HiDapE. Ribbon diagram showing the active site formed by six loops
(LI-LVI); five of them coordinate the Zn ions (LI-IV & VI). (C) Superimposition of the
structure of WT-HiDapE (black) over HiDapET (magenta). Active site Zn(II) ions are
shown as black and magenta spheres for WT-HiDapE and HiDapET, respectively.
Regions where differences are most prominent are labeled Region I (yellow) and Region
II (orange). Yellow and magenta circles highlight two disordered loop regions in the
HiDapET structure. The red dots marked disordered loop that contains conserved His
residue.
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Structure of the catalytic domain of VcDapE —The monomeric state of VcDapET
T

was confirmed by SEC (the estimated MW of 28.7 kDa). Two VcDapET structures were
determined, the apo- and the dinuclear Zn(II)-loaded form. The final models for both
apo- and Zn(II)-loaded VcDapET included two molecules of the catalytic domain in the
asymmetric unit. The two V. cholerae structures are virtually identical and superimpose
with the average rmsd of 0.25 Å for 265 equivalent C atoms suggesting that binding of
Zn(II) does not induce any major structural changes (Figure 13A). The structures of the
catalytic domains of both apo- and Zn(II)-loaded VcDapET closely resemble that of the
catalytic domain of active WT-HiDapE (PDB ID 3IC1). Superimposition of the Zn(II)loaded VcDapET structure and Zn(II)-loaded HiDapET shows that they also overlay
closely with (the average rmsd of 0.81 Å for 248 equivalent C atoms, Z-score 17,
sequence similarity 59%) (Figure 3B). Likewise, the structure of Zn(II)-loaded VcDapET
is almost identical to that of the catalytic domain of the full-length HiDapE with rmsd of
1.15 Å. The similarity between these structures is especially apparent within the active
site region of Zn(II)-loaded VcDapET as the active site structure differs by only ~0.45 Å
rmsd with the active site of HiDapET and ~0.4 Å with the WT-HiDapE (Figure 13A and
B). Similarly to HiDapET, the most flexible regions of the protein are Region I and
Region II. Region I corresponds to the engineered loop (the connector) where the deleted
dimerization domain is replaced with two glycines. Region II (residues 210-224) forms
a loop overhanging the active site metal ions, which includes residues 211-213 that form
part of loop V (vide infra) (Figure 13B).
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The active sites of HiDapE and VcDapE —The sequence identity of HiDapE and
T

T

VcDapE is high (59%), and the residues comprising the active site are fully conserved.
The active site of DapE is located in the center of the catalytic domain above the centrally
located parallel strands of the -sheet and is formed by six loops [loop I (H. influenzae
notation, residues 68-75), loop II (residues 95-102), loop III (residues 132-141), loop IV
(residues 162-174), loop V (residues 322-328 in HiDapE) and loop VI (residues 341-355)]
(Figure 12B). With the exception of loop V that does not interact with the zinc ions, the
remaining loops contribute the conserved residues that coordinate the metal ions (Figures
12B, 12C & 13B). Interestingly, loops I-IV and VI are in virtually identical orientations
in both VcDapET and HiDapET and overlay very well with the corresponding loops in the
WT-HiDapE. A change is observed in loop V which in VcDapET adopts a confirmation
that is significantly different from the one observed for WT-HiDapE (Figures 12A & 13B)
(in HiDapET this loop is disordered). The active site of Zn(II)-loaded VcDapET contains a
(μ-oxygen)(μ-carboxylato)dizinc(II) core with one terminal carboxylate and one histidine
residue at each metal site ([ZnZn(VcDapET)]), that is identical to the active site observed
for WT-HiDapE.63 The main difference between the active sites in the two Zn(II)-loaded
H. influenzae structures (WT-HiDapE and HiDapET) and [ZnZn(VcDapET)] is the
presence of additional electron density in chain A, which is overlapping with the bridging
water/hydroxide molecule observed in chain B and WT-HiDapE. The 2Fo-Fc and Fo-Fc
electron density maps were quite clear and indicate that a small molecule (most likely
ethylene glycol or a partially disordered glycerol molecule) (Figure 3C) displaces the
bridging water/hydroxide molecule in the [ZnZn(HiDapE)] and [ZnZn(HiDapET)]
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structures. Both of these compounds were present in the cryoprotectant solution. Based
on the best fit, an ethylene glycol molecule was modeled in the active site resulting in
distorted tetrahedral coordination geometry for Zn1, which is bound by the carboxylate
Figure 13. X-ray Crystal Structures of VcDapET. (A) Superimposition of apo-VcDapET
(blue) over [ZnZn(VcDapET)] (cyan), showing the identical nature of the catalytic
domains. Zinc atoms for VcDapET are shown as black spheres. (B) Comparison of
[ZnZn(VcDapET)] (cyan) and [ZnZn(HiDapET)] (magenta). Regions I (yellow) and II
(orange) identify the areas where the most significant differences between the two
structures exist. Six loops (LI-LVI) forming the active site are labeled. Zinc atoms for
VcDapET are shown as black spheres while the residues coordinating the metal ions are
shown as lines. (C) Close-up view of the active site environment of the
[ZnZn(VcDapET)] with the 2Fo−Fc electron density map (with the Zn ions and ethylene
glycol molecules omitted from the calculation). (D) Close-up view of residues from
loops I-IV and VI interacting with the Zn(II) ions in the structure of [ZnZn(VcDapET)].
(E) The 2Fo-Fc (blue, 1 σ) and Fo-Fc electron-density maps (red and green at -3σ and 3σ)
of the LV loop region in VcDapET.
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oxygen atoms OD1 of D101 and OE1 of E164 as well as a nitrogen atom NE2 of H68.
Zn2 adopts a distorted trigonal bipyramidal geometry and is coordinated by the bridging
O2 oxygen atom from ethylene glycol, a nitrogen atom NE2 of H239, two oxygen atoms,
OD2 from D101 and OE2 from E136, and the O1 oxygen atom of ethylene glycol (Figure
3D). The Zn1-Zn2 distance is 3.39 Å.
Molecular Modeling and Dynamics—MD calculations were performed for five
proteins: VcDapET, HiDapET, WT-VcDapE, WT-HiDapE and AAP. After equilibration,
the rmsd values for the main-chain atoms of [ZnZn(VcDapET)] and [ZnZn(HiDapET)]
were compared with the original X-ray structures and only small changes were observed.
Similarly, small changes were seen after equilibration of VcDapE and HiDapE as well as
AAP, which is monomeric and contains a single catalytic domain. Since only the two
truncated proteins were catalytically inactive, particular attention was given to how these
proteins differed from the other three. Figure 4 shows the results of the 5 ns molecular
dynamics simulations of the truncated proteins and comparisons to their crystallographic
temperature factors. The thickness of the line indicates the flexibility of the structure at a
given point during simulation (Figure 14A and B). The portions of [ZnZn(VcDapET)] that
have the greatest flexibility are the created dimerization domain loop which was excised
and the active site loop V (Figure 13). This is consistent with the crystallographic atomic
displacement parameters indicating that the most dynamic portions includes residues 177187 and loop V (Figure 14C). Compared to the other three structures, the two truncated
proteins have greater flexibility in both of these loops (Figure 14) than the catalytically
active domains (Figure 15).
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Mutation of the Loop V Residue T325—Since both X-ray crystallographic and
MD simulations suggested that loop V flexibility increases in VcDapET and HiDapET, it
was hypothesized that this loop plays an important role in constituting the active site and
possibly substrate recognition and/or transition-state stabilization. Since T325 in HiDapE
is centrally positioned in loop V directly above the dinuclear Zn(II) site (Figure 16), the
site-directed mutants T325A, T325S and T325C were prepared and purified. The kcat
value obtained for T325A using L,L-SDAP as the substrate was 4 ± 0.5 s-1 with a
corresponding Km value of 2.1 ± 0.2 mM while the kcat value obtained for T325S was 2.9
± 0.3 s-1 with a Km value of 3.0 ± 0.3 mM. Interestingly, when T325 was replaced by
cysteine, no enzyme activity was observed under standard assay conditions. CD spectra
obtained for each mutant enzyme plus WT-HiDapE, indicate that there is no significant
structural change in the mutant enzymes compared to WT-HiDapE (Figure 17, Table 3).
These data confirm that T325 and hence the position of loop V is important for the active
site organization and catalysis.
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Figure 14. Diagrams showing regions of flexibility in truncated DapE proteins. (A)
MOLMOL diagram of [ZnZn(VcDapET)] molecular dynamics. (B) MOLMOL diagram
of [ZnZn(HiDapET)] molecular dynamics (the thickness of the line is proportional to the
variation of the protein structure during the simulation). The crystallographic
temperature factors indicating that the most dynamic (in red) and the most rigid (in blue)
parts of the protein : (C) [ZnZn(VcDapET)]. (D) [ZnZn(HiDapET)].
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Figure 15. Molecular dynamic simulations showing regions of flexibility in catalytic
domain. (A) [ZnZn(VcDapE)]. (B) [ZnZn(HiDapE)]. (C) AAP. The thickness of the
line is proportional to the variation of the protein structure during the simulation.
AS indicates the active site area, LVeq. equivalent of the LV loop in HiDapE).

Figure 16. The active site of WT-HiDapE showing loop V. T325 resides on loop V
directly over the dinuclear active site.
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Figure 17. Circular Dichroism spectra of WT DapE (—), T325A (∙∙∙), T325C ( - ) and
T325S (-∙∙∙).
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Table 3. Circular dichroism spectroscopy analysis of WT DapE and threonine mutants.
Helix 1

Helix 2

Strand 1

Strand 2

Turns

Unordered

Total

Wild
0.24
0.05
0.20
0.12
0.17
0.23
Type
0.23
0.07
0.19
0.12
0.15
0.23
T325A
0.23
0.05
0.18
0.12
0.19
0.22
T325C
0.30
0.06
0.17
0.11
0.14
0.21
T325S
Results are shown as proportions of each protein predicted to be folded in each of the
indicated secondary structural conformations, or predicted to be unordered.

1.01
0.99
0.99
0.99

Discussion
Sequence comparison of all M20 classified metallopeptidases and the M28 family
of dinuclear Zn(II)-dependent metalloproteases, which include AAP and CPG2 62, 64,
shows that all of the metal coordinating residues are strictly conserved.53, 67b, 79. Unlike
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AAP, which is monomeric, DapE enzymes form dimers where each subunit consists of
two functional domains: a larger catalytic domain, which houses the active site and a
dimerization domain that forms the dimer interface (Figure 12A). The location and
architecture of the catalytic domain and the dinuclear Zn(II) active site in dimeric WTHiDapE is nearly identical to the catalytic domain and the active site of monomeric
AAP.64a, 80 The catalytic domain of HiDapE is composed of residues 1–179 and 293–376
where the core of the catalytic domain contains an eight-stranded twisted β-sheet that is
sandwiched between seven α-helices. The active site is located in the center of the
catalytic domain above the centrally located parallel strands of the -sheet and is
constituted by six loops. With the exception of loop V that encloses the active site from
the top and does not interact with the zinc ions, the remaining loops contribute the
conserved residues that coordinate the metal ions (Figure 12B). The dimerization domain
of HiDapE consists of a 114-residue insertion into the catalytic domain and is connected
to the catalytic domain by two short loops. Since the dimerization domain is located
away from the active site and has only limited interaction with the catalytic domain via
loop V, it is unclear whether this domain plays any role in catalysis. Such a role for the
dimerization domain would require a major conformational change to bring the
dimerization domain residues into the active site. While this is possible, the time frame
would be well beyond the range of atomistic MD simulations.
To address this issue we engineered DapE enzymes by removing their
dimerization domains (HiDapET, VcDapET). The nested truncation was designed based
on WT-HiDapE crystal structures with the goal of preserving the catalytic domain
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structure and keep its active site intact. The HiDapE and VcDapE constructs expressed
T

T

well, were purified, the monomeric states of both proteins in solution was confirmed and
their catalytic activities examined. Surprisingly, we could not detect enzyme activity for
either truncated variant towards L,L-SDAP, whereas WT-HiDapE exhibited kcat and Km
values in good agreement with those previously reported.67b For comparison purposes,
the kcat and Km were also determined for WT-VcDapE and found to be similar to the
values reported for WT-HiDapE. These data suggest that the deletion mutants have
significantly diminished catalytic activity or are fully catalytically inactive.
To understand the structural basis of the observed absence of catalytic activity of
both engineered enzymes, we determined the crystal structures of the truncated forms of
HiDapET ([ZnZn(HiDapET)]) and VcDapET ([ZnZn(VcDapET)]) along with the apo-form
of VcDapET. These structures reveal that the catalytic domain is indeed unchanged,
including complete structural preservation of the catalytic site and metal core. It is clear
that deletion of the dimerization domain does not compromise the catalytic domain
structure. The structure of [ZnZn(HiDapET)] is virtually identical to the catalytic domain
the WT-HiDapE with an rmsd of 0.8 Å for 248 equivalent C atoms. Interestingly, the
newly determined structure of [ZnZn(VcDapET)] also shows high similarity to the
catalytic domain of WT-HiDapE with an rmsd of 1.15 Å for 246 equivalent C atoms.
Since the structures of VcDapET were determined in both the apo- and dinuclear Zn(II)loaded forms, it is evident that removal of either the dimerization domain or the metal
cations does not alter the overall structure of the catalytic domain. The dinuclear Zn(II)
active sites in both HiDapET and VcDapET are nearly identical to each other with Zn-Zn
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distances of ~3.40 Å. These Zn-Zn distances are comparable to those observed for AAP
(3.45 Å), HiDapE (3.33 Å) and carboxypeptidase G2 (CPG2) (3.25 Å).64b, 79b Similar to
AAP, HiDapE, and CPG2 one of the Zn(II) ions in [ZnZn(VcDapET)] adopts a distorted
tetrahedral geometry while the second Zn(II) ion is trigonal bipyramidal. Identical to
CPG2, HiDapE, and AAP each zinc ion is coordinated by one imidazole group (H68 for
Zn1 and H239 for Zn2) and the oxygen atoms of E164 for Zn1 and E136 for Zn2. Both
zinc ions are bridged by D101 and a single oxygen atom of ethylene glycol (in the
molecule one, chain A) or water molecule (in the second molecule, chain B). Overall the
[ZnZn(VcDapET)] structure confirms that the metal ions form a (μ-oxygen)(μcarboxylato)dizinc(II) core similar to HiDapE, AAP, and CPG2 81, and indicates that the
active site catalytic unit is intact in the truncated forms of DapE. Therefore, the lack of
the catalytic activity is puzzling and clearly is not due to missing a key element in the
HiDapET and VcDapET dinuclear active site.
Comparison of the [ZnZn(HiDapET)] and [ZnZn(VcDapET)] structures with that
of WT-HiDapE (PDB ID 3IC1) (Figure 12C & 13B) reveals that one of the six loops
comprising the catalytic core, loop V (residues 210-214 in HiDapET and 211-215 in
VcDapET, and corresponding to 321-325 in HiDapE) exist in significantly different
orientations than that observed in WT-HiDapE. Interestingly, this loop is also partially
disordered in the structure of HiDapET, while in VcDapET structures its conformational
flexibility is signified by the double conformation of the main chain Gly 213 (peptide
flip). In our previous studies, we proposed that this loop might be involved in the
positioning and stabilization of the substrate in the active site, therefore the loop

47
conformation might be critical for proper substrate binding and positioning as well as
stabilization of the transition-state during the catalytic cycle.63 This is supported by two
loop V mutations (T325A, T325S) that show similar Km to WT but significantly reduced
(25-50 times) kcat values. These data suggest that the substrate is bound with similar
specificity, but is not effectively presented to the catalytic core for successful catalysis.
Since the same region is affected in both HiDapET and VcDapET, where loop V is out of
place compared to the WT-HiDapE, we hypothesized that this region is important for
catalysis. Both of the observed orientations and the greater flexibility of this loop
(Figures 13B & 14) seem to be due to the lack of interactions with specific portions of the
dimerization domain. Several interactions may be particularly critical. First, loop V in
WT-HiDapE is partially held in position by the anti-parallel beta strands (β7 and β12)
and interactions with a loop connecting β7 with the dimerization domain. These contacts
are missing in the truncated protein as portions of strands β7 and β12 have been
transformed into a deletion-derived loop and  helix (Figure 13B). Loop V in WTHiDapE is also held in place by the loop from the dimerization domain (residues 223 to
228) (Figure 16). These contacts are also missing in the truncated protein.
Interestingly, the structure of WT-HiDapE contains a sulfate ion located at the
interface of the catalytic and dimerization domains and positioned very closely to loop V.
The sulfate binding may have biological relevance and might indicate region where the
L,L-diaminopimelic acid moiety of the substrates binds. Several residues from both
domains interact with this sulfate ion. These include Arg178 (NE), Arg179 (NH), and
Gly324 (amide NH; residue in loop V) from the catalytic domain and Arg258 (NH) from
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the dimerization domain (corresponding to Arg179, Arg180, Gly325 and Arg259 in WTVcDapE) (Figure 16). This interaction is completely absent in the structure of the
[ZnZn(VcDapET)] and residues Arg178 and Arg179 are part of the deletion-derived
distorted  helix, whereas Gly214 (corresponding to Gly324 in WT-HiDapE) located
within loop V does not form any observable interactions (Figure 16).
Another indication that the specific orientation of loop V may be crucial for
catalysis comes from MD simulations of the truncated DapE structures compared to WTDapE and AAP (Figure 15). Consistent with the large crystallographic temperature
factors, the greatest flexibility in the truncated forms of DapE is observed in the
engineered loop created to replace the deleted dimerization domain and loop V, which
directly overhangs the dinuclear active site (Figure 14C and D). For comparison, loop V
in the apo-structure of NmDapE (PDB entry 1vgy) is well ordered and positioned such
that it allows two arginine residues (Arg179, Arg259 corresponding to the pairs
Arg178/Arg258 and Arg179/Arg259 in HiDapE and VcDapE, respectively) to closely
approach the active site. It is highly likely that these Arg residues, which are semiconserved (Arg178) or conserved (Arg259) in DapEs, might interact with the carboxylate
moieties of the substrate. Conserved Arg residues were shown to be essential to interact
with substrate in human aminoacylase-1 (Acy1).82 Interestingly in AAP, which exists as
a monomeric protein of only the single catalytic domain, there is a loop residing directly
over the dinuclear zinc active site that corresponds to loop V in DapE. This loop is very
rigid, unlike loop V in DapE, and appears to be held in place by an internal disulfide
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bridge formed between C223 and C227 (Figure 18). A decrease in dynamic flexibility
due to changes in quaternary structure has been suggested for other protein.83
Apart from loop V, an additional loop might play an important role in the
catalysis. Studies on Acy1, another dimeric member of the M20 family, showed that the
dimerization domain contributes to the active site probably by interacting with the
substrate.82 Lindner et al.82 showed that the alanine mutant of His206, which is located at
the center of the loop, rendered the enzyme nearly inactive. An equivalent histidine
residue is conserved in DapE enzymes (H194 in HiDapE and H195 in VcDapE), but it is
disordered in the WT-HiDapE structure.63 Modeling of this disordered loop region
(Figure 12A) positions H194 roughly ~13Å from the active site core, which is likely too
far to interact with the substrate. However, it is possible that this loop can rearrange upon
substrate binding as was reported for Acy1 and Sapep.82, 84
Evidence for such a loop movement can be gleaned from the structure of apoNmDapE where this loop is positioned within 8 Å of the active site. These data suggest
that this His residue may also play an important role in DapE enzymes by interacting
with the substrate. This hypothesis is consistent with DapEs structural design as the
presence of the inter-domain clefts and connectors would allow for significant movement
of this domain. Confirmation of the role of His194 in substrate recognition and binding
must await a structure of DapE in complex with a substrate analog.
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Figure 18. The role of the dimerization domain in the stabilization of loop V in WTHiDapE. (A). Superimposition of the WT-HiDapE (gray) and VcDapET (cyan) structures
is shown. Loop V of WT-HiDapE and VcDapET is labeled as HiLV and VcLV,
respectively. WT-HiDapE residues interacting with the sulfate ion (stick model) are
shown as gray lines. Corresponding residues in VcDapET (except for R258 that is absent
in the deletion mutant) are shown as yellow (R179 and R180) and orange (G214) lines.

(B) Specific orientation of the active site loop V in VcDapET and the corresponding loop
in AAP. Overlay of the VcDapET (cyan) and AAP (purple) structures is shown. The
AAP loop and VcDapET loop V are labeled as ApLV and VcLV, respectively.
Stabilization of loop V in AAP by a disulfide bridge is indicated where Cys223 and
Cys227 of AAP and the residues involved in zinc-binding in VcDapET are shown as
sticks. Zinc ions of VcDapET are shown as black spheres. Zinc-bound ethylene glycol
was omitted for clarity.
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In conclusion, removal of the dimerization domain in DapE enzymes renders the
enzyme inactive, even though the resulting truncated proteins have structures of the
catalytic domain that are remarkably similar to WT-DapE and AAP. In fact, the
dinculear Zn(II) site in the truncated DapE enzymes is nearly identical to those observed
for AAP and WT-HiDapE. Therefore, one would expect that the active site should be
capable of catalyzing a hydrolytic reaction and yet no activity is detected. This suggests
that positioning of the substrate in the active site is critical for the catalytic reaction to
occur. Analysis of the structures HiDapET and VcDapET reveals that loop V is much
more flexible in the truncated enzymes than WT-DapE due to the lack of interactions
provided by the dimerization domain. These data suggest that the dimerization domain
functions to restrict the conformational freedom of the loop V region and may contribute
residues to the active site environment (H194, R179, R258, T325) that are important for
substrate recognition, and binding. Designing small molecules inhibitors that interact
with this active site loop V region as well as the dinuclear metal center, or disrupting
dimer formation may lead to more potent DapE inhibitors that can function as
antibacterial agents.

CHAPTER THREE
INHIBITION OF THE DAPE-ENCODED N-SUCCINYL-L,LDIAMINOPIMELIC ACID DESUCCINYLASE FROM NEISSERIA
MENINGITIDIS BY L-CAPTOPRIL
Introduction
The discovery of penicillin in 1929 was one of the greatest advances in
therapeutic medicine considering the dramatic decrease in morbidity and mortality.85
Unfortunately, conventional wisdom predicted that bacterial resistance to antibiotics was
inevitable. The first strains of bacteria to develop resistance to penicillin were identified
in 1940, less than 20 years after its discovery.86 Bacteria have several means of
developing resistance to antibiotics such as mutating existing genes (point mutations,
deletions, inversions, insertions, etc.) or by acquiring new genes from other strains
(horizontal gene transfer).16 Therefore, the excessive and often unnecessary use of
antibiotics in humans and animals accelerates the emergence of antibiotic resistant
bacterial strains.30 Since, nearly all newly developed antibiotics are simply structural
variants of previously employed antimicrobial agents, many of them targeting the same
enzymatic pathways, the risk of bacteria quickly developing resistance is very high.4 In
fact, several pathogenic bacteria, some of which were thought to have been eradicated,
have made a significant resurgence due to bacterial resistance to antibiotics.4, 44
According to the CDC, several bacterial strains currently exhibit multidrug resistance
52
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with more than 60% of hospital acquired infections in the United States caused by the socalled ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter
species).12
To alleviate the problem of antibiotic resistance, it is urgent that new enzymatic
targets in yet unexplored bacterial synthetic pathway be identified and specific inhibitors
be developed.87 The meso-diaminopimelate (mDAP)/lysine biosynthetic pathway offers
several potential antibacterial enzyme targets, such as the dapE-encoded N-succinyl-l,ldiaminopimelic acid desuccinylase (DapE).20, 23, 27 The products of this pathway, mDAP
and lysine are essential components of the peptidoglycan cell wall for Gram-negative and
most Gram-positive bacteria, providing a link between polysaccharide strands.2, 20, 29
DapE genes have been identified in a large number of pathogenic Gram-positive and
Gram-negative bacteria including all of the ESKAPE pathogens and sequence alignment
of these DapE genes reveals a minimum of 49% identity.32, 37, 42, 55b, 64a, 88 Deletion of the
gene encoding for DapE is lethal to Helicobacter pylori and Mycobacterium smegmatis
even in the presence of lysine supplemented media.55 Therefore, DapEs appear to be
essential for bacterial cell growth and as there are no similar biosynthetic pathways in
mammals, DapEs are potential targets for inhibitors that may possess antimicrobial
activity.27
DapEs are metalloenzymes that catalyzes the hydrolysis of N-succinyl-L,Ldiaminopimelic acid (SDAP), forming L,L-diaminopimelic acid and succinate.29 DapEs
have been purified from multiple sources but the best characterized enzyme is the DapE
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from Haemophilus influenzae (HiDapE), which is a homodimeric enzyme (subunit Mr =
41.6 kDa) and requires two Zn(II) ions per mole of polypeptide for full enzymatic
activity.32 The X-ray crystal structures for both the mono and dinuclear Zn(II) forms of
HiDapE have been reported.63 In the dinuclear Zn(II) form, each Zn(II) ion adopts a
distorted tetrahedral geometry coordinated by one imidazole (H67 for Zn1 and H349 for
Zn2) and one carboxylate group (E163 for Zn1 and E135 for Zn2). Both Zn(II) ions are
bridged by an additional carboxylate groups (D100) and a water/hydroxide, forming a (μaquo)(μ-carboxylato)dizinc(II) core with a 3.3 Å Zn-Zn distance.37 To date, few
inhibitors of DapE enzymes have been reported and no X-ray structural data exists for a
DapE enzyme in the presence of any inhibitor.
The design of highly specific, tight binding inhibitors of DapE enzymes hinges on
the potential inhibitor's ability to bind to the metal ions in the active site. L-captopril, an
angiotensin-converting enzyme (ACE) inhibitor, was shown to be a potent inhibitor of
HiDapE, (IC50 of 3.3 μM and a measured Ki of 1.8 μM) and showed a dose-responsive
antibiotic activity towards E. coli.42 Several factors are important for L-captopril
interactions with the active site metal ions of DapE, some of which are metal
coordination geometry, the open metal coordination sites (i.e. those filled by a
water/hydroxide molecules), and the number of active site metal ions. Therefore, we
have analyzed the binding of L-captopril to DapE using both spectroscopic and X-ray
crystallographic evidence. These data provide insight into L-captopril binding to the
active site metal ions as well as adjacent amino acid residues, affording new information
towards the rational design of new, more potent DapE inhibitors.
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Materials and Methods
Materials. D,L-α,ε-Diaminopimelic acid (98% pure), succinic anhydride and ion
exchange resin (Dowex 50WX8−200,H+ form) were purchased from Sigma. 2Naphthalenesulfonic acid 1-hydrate (98%) was purchased from TCI Microcrystalline
cellulose was purchased from Merck. All other chemicals used in this study were
purchased from commercial sources and were of the highest quality available. SDAP
was synthesized using the procedure described by Lin et al. 59 providing an overall yield
of 41%.
Cloning, expression and purification of DapE. The HiDapE enzyme was
expressed and purified as described previously.89 The DapE gene from Neisseria
meningitidis (NmDapE) was cloned into the pMCSG7 vector using the Ligation
Independent Cloning method.90 The primers used were: 5’- TAC TTC CAA TCC AAT
GCC GCA GCT GCA GCT GCA AAA GAA AAA GTG GTT TCG TTG GCA CAA G
- 3’and 5’- TTA TCC ACT TCC AAT GTT AGT TAG CTA TCC AAT AAA TTC ACT
AAC ATT TTG TG-3’. The PCR product was purified using the QIAquick PCR
Purification Kit (Qiagen) to remove the primers and dNTPs from the PCR reaction. T4
polymerase was employed to create overhangs on the PCR fragments. The resulting
plasmid was transformed into BL21(DE3)/magic E. coli competent cells and grown in
Luria-Bertani Broth (LB) media containing ampicillin (150 µg mL-1) and kanamycin (25
µg mL-1) at 37 ˚C to an A600 of 0.7 with shaking. IPTG was added (0.4 mM) and culture
growth was continued for 16 h at 18 ˚C. Cells were recovered by centrifugation
(12,000g) for 15 min. at 4 ˚C using a Beckman Coulter Avanti J-E Centrifuge. NmDapE
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was purified according to the standard protocol for Ni-NTA affinity chromatography and
all steps were performed at 4 ˚C.91 The His6-tag was removed by treating each enzyme
with His6-tagged TEV protease for 16 h at 4 ˚C in 50 mM HEPES, pH 8.0. Cleaved
protein was separated from His6-tagged TEV using Ni-NTA affinity chromatography.
Enzymatic Assay. The specific activity of HiDapE and NmDapE was determined
using a 50/50 mixture of D,D and L,L-SDAP as the substrate in 50 mM Phosphate buffer
(PPi), pH 7.5 as previously described.67b The kinetic parameters Vmax and Km were
determined by quantifying the amide bond cleavage (decrease in absorbance) of L,LSDAP at 225 nm ( = 698 M-1 cm-1) in triplicate. Enzyme activities are expressed as
units/mg where one unit is defined as the amount of enzyme that releases 1 μmol of L,LSDAP at 30 ˚C in 1 min. Catalytic activities were determined with an error of ± 10 %.
Initial rates were fit directly to the Michaelis-Menten equation to obtain the catalytic
constants Km and kcat using Origin software.
Inhibition of NmDapE by L-captopril. The kinetic parameters v (velocity), kcat
(Vmax/[E]0), Km (Michaelis constant), and Ki (inhibition constant) were determined in 50
mM PPi at pH 7.5 spectrophotometrically by recording the initial velocity of the
hydrolysis of L,L-SDAP at 25 oC in triplicate.92 L-captopril concentrations ranged from
0 to 0.1 mM. The linearity of the progress curves for product formation both in the
absence and presence of inhibitor indicated that L-captopril is in rapid equilibrium with
NmDapE. The initial rates were plotted against substrate concentration and the kinetic
constants were calculated using Origin software.59, 67
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Co(II)-Substituted DapE samples. Apo-DapE was prepared by extensive dialysis
for 72 h at 4 ˚C against 10 mM EDTA in 50 mM HEPES buffer, pH 7.5. DapE was then
exhaustively dialyzed against metal-free (Chelex-100 treated) 50 mM HEPES buffer, pH
7.5. Any remaining metal ions were estimated by comparing the activity of the apoenzyme with a sample that had been reconstituted with Zn(II). DapE incubated with
EDTA typically had less than 5% residual activity after dialysis. The mono and
dicobalt(II)-forms of HiDapE and NmDapE were prepared using apo-DapE samples that
were incubated with CoCl2 (99.999%; Strem Chemicals, Newburyport, MA) for 30
minutes at 25 ˚C prior to exhaustive dialysis into Chelex-100 treated buffer as previously
reported.93
UV-Visible Measurements. Electronic absorption spectra were recorded on a
Shimadzu UV-2450 spectrophotometer equipped with a temperature controller (25 ˚C).
A protein concentration of 1.5 mM in 50 mM HEPES buffer, pH 7.5 was used to obtain
each spectrum. The electronic absorption spectra of [Co_(HiDapE)], [CoCo(HiDapE)],
[Co_(NmDapE)], and [CoCo(NmDapE)] were recorded in both the absence and presence
of L-captopril, and the absorption due to apo-enzyme was subtracted.
EXAFS Spectroscopy. EXAFS spectra of a 1 mM sample of [ZnZn(HiDapE)]
frozen in polycarbonate cuvets (24 x 3 x 1 mm) with a 0.025 mm Mylar window covering
face, were collected at the Stanford Synchrotron Radiation Laboratory (SSRL) on
beamline 7-3. The SPEAR storage ring operated in a dedicated mode at 3.0 GeV. The
Si[220] crystal monochromator was detuned to 50% maximum reflectivity for harmonic
rejection. On beamline 9-3, a focusing mirror provided harmonic rejection. The edge
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regions, for multiple scans obtained on the same sample, were compared to ensure that
the sample was not damaged by exposure to X-ray radiation. EXAFS analysis was
performed using EXAFSPAK software according to standard procedures, using E0 =
9670 eV for k-scale definition.
Electron Paramagnetic Resonance Spectroscopy. Electron paramagnetic
resonance (EPR) spectra were recorded at 4.5 - 35 K, 9.63 GHz (ER4116DM resonator
with B0B1), 9.37 GHz (ER4116DM resonator with B0||B1), or 9.39 GHz (SHQ
resonator) using 1.2 mT (12 G) magnetic field modulation at 100 kHz with phasesensitive detection on a Bruker EleXsys E600 spectrometer equipped with an Oxford
Instruments ESR900 helium flow cryostat and ITC503 temperature controller. The SHQ
resonator has a significantly higher B1 for a given microwave power than the ER4116DM
resonator (we estimate by a factor of about 5). Background signals were collected on
samples of frozen buffer and subtracted.
Magnetic Circular Dichroism Studies. The Magnetic circular dichroism (MCD)
instrument consists of a JASCO J815 spectropolarimeter and an Oxford Instruments
SM4000 cryostat/magnet. Variable-temperature variable-field (VTVH) MCD data were
collected at increments of 0.5 Tesla (T) from 0 to 7.0 T and at temperatures (nominally)
of 1.5, 3.0, 6.0, 12, 24 and 48 K. Spectra were collected at 1.0 nm band width and were
scanned at 50 nm/min using a one second time constant. The sample cell has a 0.62 cm
path length. Each spectrum was corrected for any natural CD by subtracting the zerofield spectrum of the sample. Even when there is no sample present the instrument the
baseline exhibits a small deviation from zero that is both field- and wavelength-
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dependent. Therefore, each spectrum was also corrected by subtraction of a spectrum
recorded at the same magnetic field but with no sample present. The MCD spectra were
fit to the minimum number of Gaussian peaks using GramsAI 9.1 software after
converting the spectra to wavenumber units. In the fitting process, a minimum number of
Gaussians were fit to achieve a satisfactory composite spectrum. Fitting of the VTVH
MCD data was achieved using a Fortran program, VTVH 2.1.1, written by Mark Riley.94
The spin Hamiltonian and additional details of the fitting program have been described
previously.95 The fits were tested for robustness once a complete set of parameters had
been obtained. To do this, the initial parameters were set to the best fit parameters and
then all allowed to float. Subsequently, one key parameter such as J, D, Mxy, Mxz, Myz was
chosen and its initial value was set differently after which the fit process was repeated.
Percent polarization for a given fit was calculated from Mxy, Myz and Mxz using %Mx =
(Mxy•Myz)2/[(Mxy•Mxz)2+(Mxy•Myz)2+(Mxz•Myz)2]. My and Mz were calculated
correspondingly.96 Finally, the VTVH MCD data fitting program used a spin
Hamiltonian that included the term H = -2J S1S2.
Protein Crystallization. Prior to crystallization, a 25 mg/ml NmDapE protein
sample was incubated with 3 eq. of Zn2+ ions and left on ice for 20 minutes to equilibrate.
Zinc-loaded NmDapE was screened against three hundred commercially available
conditions (Index HT and PEG/Ion HT from Hampton Research and Wizard TM from
Emerald Biosystems) using a Mosquito liquid handling robot with 96 plates.97 Several
crystallization conditions were characterized yielding diffraction quality crystals. All
crystals were screened and data were collected on the best diffracting crystals, which
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were grown by the sitting-drop vapor-diffusion method at 16 ˚C using 400 nl of a
precipitant solution (20% (w/v) PEG 3350, 100 mM HEPES pH 7.5) and 400 nl of
[ZnZn(NmDapE)]. X-ray quality crystals appeared within 2 weeks. Crystals of
[Zn_NmDapE] were also crystallized by the sitting-drop vapor-diffusion method at 16 ˚C
but with a 400 nl precipitant solution (15% (w/v) PEG 3350 100 mM Succinic acid pH
7.0) and 400 nl of a protein providing crystals within 2 weeks. Crystals of
[ZnZn(NmDapE)] in complex with L-captopril were obtained by mixing 400 nl of a
precipitant solution (0.2 M ammonium acetate, 0.1 M TRIS pH 8.5, 25% (w/v) and
polyethylene glycol 3350 in a 1:1 ratio with a solution of [ZnZn(NmDapE)] incubated
with a 20 mM solution of L-captopril (50 mM HEPES pH 7.5, 150 mM NaCl) with
crystals appearing within 3 weeks.
Structure Solutions and Refinement. The X-ray data were collected at the 19-ID
beamline of the Structural Biology Center at the Advanced Photon Source.37 All data
were processed and scaled using HKL3000. All structures described in this manuscript
were determined by the molecular replacement method and refined by slight variation of
the same protocol. Molecular replacement searches were completed with the program
MOLREP within the CCP4 suite using the apo-crystal structure of NmDapE as a template
(PDB id 1vgy).37 The asymmetric unit of [Zn_(NmDapE)] (space group P212121)
contains a dimer, while crystals of [ZnZn(NmDapE)] and [ZnZn(NmDapE)] in complex
with captopril both crystallized in the C2221 space group and contained only one subunit
of the dimer. Several rounds of rebuilding and readjusting using COOT 98 and
refinement using programs REFMAC 99 and PHENIX 68 were required to improve the
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initial models. The final models were refined against all reflections using the program in
the resolution ranges except for 5% of the reflections, which were randomly selected and
used to monitor Rfree. The final refinement statistics are presented in Table 4. Analysis
and validation of all structures were performed with the aid of PROCHECK100 and
MOLPROBITY.101 The refinement restraints for the L-Captopril structure were created
with the assistance of the program Coot and were generated from SMILE102 string.
PDB coordinates. The atomic coordinates for [Zn_(NmDapE)],
[ZnZn(NmDapE)] and [ZnZn(NmDapE)] bound by L-captopril were deposited in the
PDB with id (4O23, 4PPZ and 4PQA), respectively.
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Table 4. Data and Refinement Statistics for [Zn_NmDapE], [ZnZn_NmDapE] and
[ZnZn_NmDapE]-L-captopril.
Data collection statistics
Space group
Unit cell (Å)

Resolution (Å)
Wavelength (Å)
Number of observed
reflections
Number of unique reflections
Redundancy

b

Rmergea,b (%)
Rpima,b (%)
Completenessb (%)
I/σ
Phasing
phasing method
Refinement statistics
Rcryst (%)
Rfree (%)
protein residues
zinc/phosphate/sulfates ions
solvent
Rmsd from target values
bond lengths (Å)
bond angles (deg)
Average B factors (Å2)
protein
Zn
H2O
PDB ID
Ramachandran (%)c
M.F./A.A.
a

[Zn_NmDapE]

[ZnZn_NmDapE]

P212121
a = 55.3
b =111.4,
c = 132.5
39.2-2.09
0.98 Å

C2221
a = 117,
b =151.6
c = 55.5
29.4-2.0
0.98

[ZnZn_NmDapE]-Lcaptopril
C2221
a = 116.9,
b =151.5
c = 55.1
27.5-1.78
0.98

204709

202836

178375

48738

33502

46112

4.2(4.0)

6.1(5.8)

3.9(3.8)

7.4 (82.1)
4.0 (45.7)
99.1 (96.7)
17.9(1.5)

8.5 (89.9)
4.3 (59.4)
100 (100)
22.8(1.9)

6.5 (75.2)
3.3(44.2)
97.7 (99.5)
17.7(1.7)

MR

MR

MR

21.3
24.1
746
3/-/4

17.5
20.8
374
2/1/-

16.4
19.6
374
2/-/1

380

237

284

0.003
0.71

0.020
1.69

0.021
1.90

43.8
32.0
37.8
4O23
97.4/2.6

32.2
23.2
24.19
4PPZ
97.6/2/4

24.8
17.9
34.6
4PQA
97.9/2.1

Rmerge = ΣhklΣi|Ii(hkl) − 〈Ihkl〉|/ΣhklΣiIi(hkl), where Ii(hkl) is the ith observation of reflection hkl, and 〈Ihkl〉
is the weighted average intensity for all observations i of reflection hkl. and Rpim = Σhkl(1/(N −
1)1/2)Σi|Ii(hkl) − hkl|/ΣhklΣiIi(hkl).
b
Numbers in parentheses are values for the highest-resolution bin.
c
As defined by MOLPROBITY (M.F.-the most favored/ A.A additionally allowed)
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Results
Kinetic studies on [Zn_(NmDapE)] and [ZnZn(NmDapE)]. The kinetic
parameters for the [Zn_(NmDapE)] and [ZnZn(NmDapE)] were determined by
monitoring the hydrolysis of L,L-SDAP, at pH 7.5 and 25 oC. For [Zn_(NmDapE)], a kcat
value of 76 ± 10 s-1 and a Km value of 795 ± 20 µM was obtained. On the other hand,
[ZnZn(NmDapE)] exhibited a kcat of 120 ± 10 s-1 and a Km of 610 ± 11µM. For
[Zn_(HiDapE)] and [ZnZn(HiDapE)], kcat values of 80 ± 5 s-1 and 140 ± 10 s-1 were
obtained, respectively, with corresponding Km values of 730 ± 15 µM for both enzymes
(Table 5). Inhibition of NmDapE by L-captopril was examined by monitoring the initial
rates of hydrolysis of L,L-SDAP as a function of L-captopril concentration in triplicate.
The double-reciprocal plot of velocity vs. L-captopril shows a pattern characteristic of
competitive inhibition. The experimental data were fit to the Michaelis-Menten equation
for competitive inhibition reported by Cleland.103 The inhibition constant, Ki, for the
binfing of L-captopril to NmDapE was found to be 2.4 ± 0.1 µM in good agreement with
the Ki value obtained for L-captopril inhibition of HiDapE of 1.8 µM.92
Electronic Absorption Spectroscopy. Electronic absorption spectra were obtained
for [Co_(HiDapE)], [CoCo(HiDapE)], [Co_(NmDapE)], [CoCo(NmDapE)] in both the
Table 5. Kinetic constants for the [Zn_(DapE)] and [ZnZn(DapE)] from N. meningitidis
and H. Influenzae.
NmDapE

HiDapE

Kinetic constants

Zn

ZnZn

Zn

ZnZn

Km (µM)

795 ± 20

610 ± 11

730 ± 15

730 ± 15

kcat (s-1)

76 ± 10

120 ± 10

80 ± 5

140 ± 10

kcat/Km (mM-1min-1)

5,700 ± 200

11,800 ± 200

6,600 ± 200

11,400 ± 200
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absence and presence of L-captopril, since the position and molar absorptivities of the
Co2+ d-d bands reflect the coordination number and geometry of the metal ions.104 The
absorption due to apo-DapE was subtracted in all cases. The spectra of [Co_(NmDapE)]
and [CoCo(NmDapE)] recorded in the absence of L-captopril are identical to those
previously reported for [Co_(HiDapE)] and [CoCo(HiDapE)] (Figure 19A & B).67b For
[Co_(NmDapE)] two resolvable d-d transitions are observed with λmax values of 560 nm
(ɛ ~40 M-1cm-1) and a shoulder at 520 nm (ɛ ~30 M-1cm-1) while [CoCo(NmDapE)] also
exhibited an absorbance bands at 560 nm (ɛ ~130 M-1cm-1) and 520 nm (ɛ ~120 M-1cm-1).
Upon the addition of 5 eq. of L-captopril to [Co_(NmDapE)] the d-d band at 560 nm
slightly red-shifted with little or no change in the molar absorptivity (Figure 19 A).
However, when 5 eq. of L-captopril was added to [CoCo(NmDapE)], the λmax red-shifts
to 590 nm while molar absorptivity increases from ~130 to 250 M-1cm-1 (Figure 19A).
Similar spectra were recorded for [Co_(HiDapE)] and [CoCo(HiDapE)] (Figure 19B).
The UV‐Vis spectrum of [CoCo(HiDapE)] in the presence of L‐captopril was also
recorded from 250 to 400 nm; however, the characteristic S→Co2+ ligand‐to‐metal
charge‐transfer (LMCT) band, which would be expected to exhibit a molar absorptivity
of ~1000 M‐1cm‐1, was not observed due to strong protein absorption.104
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Figure 19. Electronic Absorption Spectra: ( A) a 1.5 mM solution of [Co_(NmDapE)] in
50 mM HEPES buffer, pH 7.5 in the absence (black) and presence (blue) of 5 eq. of Lcaptopril and a 1.5 mM solution of [CoCo(NmDapE)] in the absence (red) and presence
(green) of 5 eq. of L-captopril in 50 mM HEPES buffer pH 7.5.
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(B) a 1.5 mM solution of [Co_(HiDapE)] in the absence (black) and presence (blue) of 5
eq. of L-captopril in 50 mM HEPES buffer at pH 7.5 and a 1.5 mM solution of
[CoCo(HiDapE)] in 50 mM HEPES buffer at pH 7.5 in the absence (red) and presence
(green) of 5 eq. of L-captopril. The electronic absorption spectrum of apo enzyme was
subtracted in each case.
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EPR spectra of L-captopril bound to [Co_(NmDapE)], [CoCo(NmDapE)],
[Co_(HiDapE)], and [CoCo(HiDapE)]. EPR spectra of the resting forms of Co2+substituted NmDapE (Figure 20A) and HiDapE (Figure 20B) show distinct similarities.
At 13 K and non-saturating microwave power, the [Co_(NmDapE)] spectra are complex
and appear due to a moderately rhombic (E/D  0.15) MS =  1/2 signal with resonances at
g' = 5.35 (1250 G), 4.05 (1660 G) and 2.25 (3015 G), superimposed on an MS =  3/2
signal with a sharp resonance at g' = 6.5 (1030 G) and a broad derivative feature with an
estimated turning point at g'  1.15. At 4.5 K and high microwave power, the MS  1/2
signals are almost completely extinguished. This latter behavior indicates that the MS = 
1

/2 signals are due to thermal population of the MS =  1/2 Kramers' doublet at the higher

temperature and is due to an excited state with a zero-field splitting,, on the order of 10
cm-1 for [Co_(NmDapE)], and less for [Co_(HiDapE)] where some MS =  1/2
contribution is still evident at 4.5 K (1 cm-1 corresponds to 1.44 K). If the MS =  1/2
signals were ground state signals due to a distinct chemical species, rapid-passage signals
would be expected to be observed rather than disappearance or diminution of the
signals.105 The data indicate, therefore, a preferred binding site with an MS =  3/2 ground
state, suggesting a distorted tetrahedral coordination environment.105 Upon adding a
second equivalent of Co2+, a poorly resolved and apparently MS =  1/2 signal is observed
at 13 K. In addition, a very weak but clearly identifiable 59Co hyperfine pattern with Az =
90 G was observed on the low field edge of the MS =  1/2 signal, centered at g' = 7.9
(850 G; see e.g. Figure 20A, trace C), that could be due to a small amount of an
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Figure 20. EPR spectra at 9.39 GHz (SHQ resonator) of: (A) [Co_(NmDapE)] (A, B)
and [CoCo(NmDapE)] (C, D), recorded at 13 K, 0.5 mW (A, C) and 4.5 K, 100 mW (B,
D). Spectral amplitudes are shown normalized for 1/T, Pmicrowave , and eq. of Co2+
added. (B) of [Co_(HiDapE)] (A, B) and [CoCo(HiDapE)] (C, D), recorded at 13 K, 1.0
mW (A, C) and 4.5 K, 200 mW (B, D). Spectral amplitudes are shown normalized for
1/T, Pmicrowave , and eq. of Co2+ added.
A)

B).

additional MS =  3/2 signal with greal(z) ~ 2.6 or else a very rhombic (E/D ~ 1/3) MS =  1/2
signal with greal(y) ~ 2.9; the origin of the hyperfine-split signal is unclear but it was
completely insensitive to captopril and is not considered further.
In contrast to [Co_(NmDapE)] and [Co_(HiDapE)], when EPR spectra of
[CoCo(NmDapE)] and [CoCo(HiDapE)]were recorded at 4.5 K, the predominant MS = 

1
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/2 signal was clearly still observable as a rapid-passage signal that appears as an inverted

absorption-shaped feature, superimposed on the sharp MS =  3/2 signal at g' = 6.5. The
appearance of a slow-relaxing ground-state MS =  1/2 signal is consistent with the second
added eq. of Co2+ occupying a five- or six-coordinate site. There is a slight difference
between the signals from [CoCo(NmDapE)] and [CoCo(HiDapE)]. The signal from
[CoCo(NmDapE)] appears to account for the entire cobalt complement, whereas that
from [CoCo(HiDapE)] indicates that some EPR silent Co2+ is present. Further, the MS =
 3/2 signal in [CoCo(HiDapE)] is specifically and significantly smaller than in
[Co_(HiDapE)], whereas this is not the case in [CoCo(NmDapE)]. These data suggest
weak antiferromagnetic interaction between the Co2+ ions in [CoCo(HiDapE)], such that
|J| > h for some, but not all, of the population of dinuclear centers in the sample, i.e. that
there is a distribution of J that includes 0.3 cm-1. No parallel mode (B0||B1) EPR signals
were observed.
L-captopril addition was found to induce differential effects in [CoCo(NmDapE)]
and [CoCo(HiDapE)]. Upon adding L-captopril to [CoCo(NmDapE)], the sharp MS = 
3

/2 signal at g' = 6.5 is essentially extinguished but no overall signal intensity is lost

(Figure 21, traces A & B). This is consistent additional coordination of the hitherto fourcoordinate Co2+ ion but no mediation of significant ( 0.3 cm-1) exchange coupling
between the two Co2+ ions. In contrast, the addition of L-captopril to [CoCo(HiDapE)]
leads to a wholesale loss of about 30 % of the EPR intensity, with no detectable change in
line shape (Figure 21, traces C & D), signifying an increase, albeit modest, in the
exchange coupling between the two Co2+ ions.
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Figure 21. EPR spectra at 9.63 GHz (ER4116DM resonator) of [CoCo(NmDapE)] before
(A) and after (B) the addition of L-captopril; and [CoCo(HiDapE)] before (C) and after
(D) addition of L-captopril. Spectra were recorded at 4.5 K, 100 mW. Spectral
amplitudes are shown normalized for 1/T, Pmicrowave , and eq. of Co2+ added.

MCD spectra of L-captopril bound to [Co_(NmDapE)], [CoCo(NmDapE)],
[Co_(HiDapE)], and [CoCo(HiDapE)]. MCD spectra of [CoCo(NmDapE)] and
[CoCo(HiDapE)] are nearly identical in shape, band energies, and intensities (Figure 22).
It should be noted that the MCD spectra at room temperature in pure buffer (no glycerol
glassing agent) have the same bands as the low temperature spectra; however, they are
much less intense and broader. All of the bands are temperature–dependent C-terms
arising from the paramagnetic high-spin Co2+ ground states. The intense negative band at
576 nm is asymmetric due to a small component at 559 nm in [CoCo(HiDapE)] and at
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558 nm in [CoCo(NmDapE)]. This intense negative band along with an intense positive
band at 532 nm are characteristic of high-spin Co2+ in a four-coordinate, distorted
tetrahedral ligand field.106 These bands arise from the 4A2→4T1(P) d-d transition in Td
that have been split into three components by the lower symmetry environment in the
active site. The negative band at 503 nm along with a very weak positive band at shorter
wavelength are characteristic of high-spin Co2+ in a six-coordinate, distorted octahedral
ligand field.106a, b, 107 The band at 503 nm arises from the 4T1g→4T1g(P) d-d transition in
Figure 22. MCD spectra of : (A) [CoCo(HiDapE)] (top) and [CoCo(NmDapE)] (bottom)
and (B) [CoCo(HiDapE)] + 5 eq. of L-captopril (top) and [CoCo(NmDapE)] + 5 eq. of
L-captopril (bottom). All spectra were recorded at 1.3 K and 7.0 T in a 0.62 cm path
length cell. The enzymes were in a solution of 60/40 (v/v) glycerol/buffer.
[CoCo(HiDapE)] was 32 mg/mL (0.77 mM enzyme, 1.6 mM in active sites, 3.1 mM in
Co2+). [CoCo(NmDapE)] was 29 mg/mL (0.70 mM enzyme, 1.4 mM in active sites, 2.8
mM in Co2+). The units of Δε/H are M-1cm-1T-1, where the concentration of actives sites
was used. In both figures the blue trace is the experimental spectrum and the red traces
are the Gaussians used to fit the spectra.
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Oh that can broaden or split in lower symmetries. The 503 nm band does not split in
[CoCo(NmDapE)] or [CoCo(HiDapE)] but is noticeably broader in [CoCo(HiDapE)] than
in [CoCo(NmDapE)]. The very weak positive bands at 463 and 475 nm in
[CoCo(HiDapE)] and [CoCo(NmDapE)], respectively, are doublet transitions, which gain
intensity through spin-orbit coupling to the nearby spin-allowed 503 nm band.107a Despite
the similarity in the MCD spectra of [CoCo(HiDapE)] and [CoCo(NmDapE)], there is a
difference in the relative metal binding affinities between the two enzymes. When 1 eq.
of Co2+ is added to apo-NmDapE, both the six-coordinate and four-coordinate sites are
partially occupied. Addition of a second eq. of Co2+ saturates both binding sites. On the
other hand, addition of 1 eq. of Co2+ to apo-HiDapE saturates the four-coordinate site
leaving the six-coordinate site virtually empty.
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VTVH MCD data were collected at 503, 532 and 576 nm on both
[CoCo(NmDapE)] and [CoCo(HiDapE)]. The data were used to construct magnetization
plots. The VTVH MCD were fitted as previously described 88a, 94, which yield the
electronic ground state parameters for magnetic exchange coupling (J), axial (D) and
rhombic (E) zero-field splitting (ZFS). Multiple experiments were run and average
values of these parameters along with the standard deviations are given in Table 6.
Magnetic exchange coupling, if it occurs, will be strongest through the monoatomic
bridges (e.g. μ-1,1 as opposed to μ-1,3). In none of the fittings of the VTVH data from
[CoCo(NmDapE)] or [CoCo(HiDapE)] was the quality of fit improved (lower value of χ2)
by having a non-zero J (positive or negative). This strongly suggests that the bridging
oxygen atom is in the form of a μ-aqua as opposed to a μ-hydroxo. Many dicobalt(II)
complexes with either a μ-aqua or μ-hydroxo have been studied.29, 108 Aqua bridged
complexes consistently exhibit a small antiferromagnetic coupling (negative J) or no
coupling at all; whereas, hydroxo-bridged complexes consistently have a small
ferromagnetic (positive J) coupling. The ZFS parameters that were determined in the
fitting of the VTVH data from [CoCo(NmDapE)] and [CoCo(HiDapE)] were also
consistent with assignment of the 503 nm band to a six-coordinate Co2+, and the 532 and
576 nm bands to a four-coordinate Co2+. Generally the axial ZFS parameter, D, is greater
than 50 cm-1 for six-coordinate high-spin Co2+ and less than 10 cm-1 for four-coordinate
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Table 6. VTVH MCD Fitting Parameters.
[CoCo(NmDapE)]
Parameter
J (cm-1)

[CoCo(NmDapE)]

a

+ Captopril

b

[CoCo(HiDapE)]
[CoCo(HiDapE)]

c

+ Captoprild

0

-0.1

0

-0.05 ±0.04

D (cm ), 4C

3.7 ±0.6

0.05

3.7 ±1.0

4.1 ±1.5

E/D, 4C

~0

0.002

~0

0.25 ±0.14

D (cm ), 6C

>100

>50

>100

28 ±5

E/D, 6C

0.18 ±0.04

~0

0.27 ±0.04

0.08 ±0.03

Polarizations

503 nm x-pol.

505 nm na

503 nm x-pol.

505 nm z-pol.

532 nm xy-pol.

530 nm na

532 nm xy-pol.

530 nm z-pol.

576 nm xy-pol.

604 nm z-pol.

576 nm xy-pol.

604 nm z-pol.

-1

-1

a

Based on 3 independent experiments; ± one standard deviation. bBased on a single experiment. cBased on
8 independent experiments. dBased on 4 independent experiments.

high-spin Co2+.29, 106c The addition of 1 eq. (based on concentration of active sites) of Lcaptopril to either [CoCo(HiDapE)] or [CoCo(NmDapE)] has no apparent effect on the
MCD spectra. However, addition of 5 eq. of L-captopril causes the green resting enzyme
solutions to turn blue (Figure 22B). The four-coordinate Co2+ bands shift from 532, 559
and 576 nm in [CoCo(HiDapE)] to 530, 565 and 604 nm in the [CoCo(HiDapE)]-Lcaptopril complex while the four-coordinate Co2+ bands shift from 532, 558 and 576 nm
in [CoCo(NmDapE)] to 530, 565 and 604 nm in the [CoCoNmDapE]-L-captopril
complex. The six-coordinate band at 503 nm splits into two bands at 488 and 505 nm for
both [CoCo(HiDapE)]-L-captopril and [CoCo(NmDapE)]-L-captopril. There is a small
peak at 576 nm in both spectra, which is due to uncomplexed enzyme. In addition to
these band shifts, there is a roughly three-fold decrease in MCD intensity, which is not
due to any removable of metal from the enzyme by L-captopril. Finally the quality of the
optical glasses formed in the presence of L-captopril was not as high as for the resting
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enzyme alone. This resulted in MCD spectra that had considerably lower signal to noise
than in the MCD spectra of the resting enzymes.
VTVH MCD data were also collected on the 505, 530, and 604 nm bands in
[CoCo(HiDapE)]-L-captopril and only for the 604 nm band in [CoCo(NmDapE)]-Lcaptopril. Example magnetization plots and fits are shown in Figures SI-9 through SI-12.
The χ2 values for the 505 and 530 nm band fits are quite high as is the χ2 value for the
604 nm band fit in [CoCo(NmDapE)]-L-captopril. The best fits were obtained with a
small negative value for J. In addition the ZFS parameters for both the six- and fourcoordinate sites changed, but are still in the ranges expected for four- and six-coordinate
Co2+ (Table 6).
EXAFS of L-captopril bound to [ZnZn(HiDapE)]. Zn K-edge extended X-ray
absorption fine structure (EXAFS) spectra were recorded for [ZnZn(HiDapE)] in the
presence of L-captopril (Figure 23). The EXAFS data reveal an average of both metal
ion environments. The dominant peak in the Fourier transformed (FT) EXAFS data for
[ZnZn(HiDapE)] is centered at ~2.0 Å with a second shell feature at ca. 3.3 Å, identical
to previously reported EXAFS data.81 Coordination of L-captopril to [ZnZn(HiDapE)]
results in EXAFS spectra that can be fit to 5 ± 1 N/O scatterers. However, the Zn-Zn
distance increases from 3.32 to 3.40 Å. In addition, the EXAFS data for
[ZnZn(HiDapE)]-L-captopril reveal a new feature at 2.3 Å that is highly characteristic of
a direct zinc-sulfur interaction.
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Figure 23. Zn K-edge EXAFS spectra of a 1 mM solution of [ZnZn(HiDapE)] 50 mM
HEPES buffer, pH 7.5 in the absence (red) and presence (black) of L-captopril.

Crystal structures of [Zn_(NmDapE)],[ ZnZn(NmDapE)], and the L-captopril
bound [ZnZn(NmDapE)] complex. The X-ray crystal structures of [Zn_(NmDapE)], (2.1
Å), [ZnZn(NmDapE)] (2.0 Å) and the [ZnZn(NmDapE)]-L-captopril complex (1.8 Å)
were solved. These three structures along with apo-NmDapE, which was previously
determined (1vgy) 109, reveals the typical two-domain homodimer structure (either
present in the asymmetric unit, or generated by the crystallographic two-fold axis)
observed for all DapE enzymes. Comparison of all four structures of NmDapE shows
that the overall fold is well preserved and the structures of the apo, mono and di-zinc, and
L-captopril bound forms are nearly identical. Each of these structures overlay with an
rmsd for Cα atoms of 0.59 Å (apo-NmDapE over [Zn_(NmDapE)]) and 0.73Å (apoNmDapE over [ZnZn(NmDapE)] and L-captopril bound [ZnZn(NmDapE)]). Close
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analysis of the [ZnZn(NmDapE)] and [ZnZn(NmDapE)]-L-captopril structures (both were
determined from isomorphous crystals grown under similar conditions (Table 4), reveals
that inhibitor binding does not introduce any significant changes in the structure as
evidenced by a very low rmsd deviation of 0.2 Å. Furthermore, analysis of the active site
regions of the [ZnZn(NmDapE)] structure indicates that the metal ions and ligands are in
nearly identical positions. The dinuclear Zn2+ active sites in both [ZnZn(NmDapE)] and
the [ZnZn(NmDapE)]-L-captopril complex adopt identical coordination geometries to
that reported for HiDapE.37
For [ZnZn(NmDapE)], the first metal binding site, Zn1, resides in a distorted
tetrahedral geometry and is bound by the carboxylate oxygen atoms OD1 of D101 and
OE1of E164 as well as a nitrogen atom NE1 of H68. The Zn2 metal ion resides in a
distorted trigonal bipyramidal geometry and is bound by a nitrogen atom NE2 of H350,
two oxygen atoms, OD2 from D101 and OE2 from E136, and the O1 oxygen atom of
ethylene glycol. Interestingly, for [Zn_(NmDapE)] a full dimer resides in the asymmetric
unit and Zn2+ binding is different between the two active sites. In one of the active sites,
a single Zn2+ ion is bound in the first metal binding site while in the second active site
site, two Zn2+ ions are present but with occupancies modeled at 50% for Zn1 and 20% for
Zn2. These data suggest that metal binding is not sequential for NmDapE, which is
different from that observed for HiDapE.
The structure of the [ZnZn(NmDapE)]-L-captopril complex was obtained by cocrystallization of [ZnZn(NmDapE)] and L-captopril and solved to 1.8 Å resolution. The
structure reveals clear electron density corresponding to L-captopril inside the positively
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charged grove, formed between the catalytic and the dimerization domains (Figure 24).
The sulfhydryl group of L-captopril bridges between the two active site Zn+2 ions with a
Zn-S distance of 2.3 Å and a Zn2-S distance of 2.3 Å, displacing the bridging water
molecule. The carboxy-end of the proline moiety of L-captopril forms a hydrogen bonds
with N346 (ND2-O3, 3.0 Å) and the amide of G325 (N-O2, 2.9 Å). It also forms a strong
hydrogen bond with the hydroxyl of Y198 (OH-O3, 2.5Å), which reaches over from the
second subunit of the dimer. The O1 carbonyl oxygen of the L-captopril (the carbonyl
oxygen of the peptide bond) also forms a hydrogen bond with a well-ordered water
molecule (2.8Å), which is stabilized by its interaction with R179 (NH2-O 3.1 Å) and
P165 (2.6 Å)
Discussion
Because of the emergence of bacterial resistance to antibiotics used in current
standard of care, new small molecules need to be designed and synthesized that inhibit
novel antibacterial enzyme targets, such as DapE. Several structural classes that
containing different zinc-binding groups (ZBG’s) such as carboxylic acids, boronic acids,
phosphates, and thiols have been reported to inhibit DapE enzymes. Thiols are
commonly used as inhibitors for Zn2+ metalloproteins since Zn(II) is a soft acid and thiols
are soft bases.110 Examination of several thiol based compounds has led to the
identification of low micromolar inhibitors of DapE.81, 92 For example, L-penicillamine
exhibits an C50 value of 13.7 μM, and is a competitive inhibitor of HiDapE with a
measured Ki of 4.6 μM. DapE is also stereoselective with respect to the recognition of
substrate and inhibitors, as D-penicillamine provided an C50 value of 50 μM.92
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Figure 24. Structure of [ZnZn(NmDapE)] bound by L-captopril. (A) Ribbon diagram of
the homodimer of [ZnZn(NmDapE)] (subunit A in orange and subunit B in blue). The
Zn2+ ions in the dinuclear active site are shown as black spheres while molecules of Lcaptopril are shown as green sticks. (B) Close-up of the active site region showing the
hydrogen bonding interactions of L-captopril (green) with surrounding protein residues
and solvent molecule (red sphere). The active site residues are color coded (orange and
blue sticks) according to the subunit coloring, while the conserved residues binding to the
Zn2+ ions are grey. (C) Schematic drawing of the dinuclear Zn2+ active site bound by Lcaptopril (distances are displayed in angstroms).
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Similarly, L-captopril, and angiotensin-converting enzyme (ACE) inhibitor, exhibited an
C50 value of 3.3 μM towards HiDapE and is also a competitive inhibitor with a
measured Ki of 1.8 μM while D-captopril yielded an C50 value of 42 μM. Similar to
HiDapE, L-captopril is a competitive inhibitor of NmDapE with a measured Ki of 2.8 μM.
Interestingly, it has been showed recently by Uda et al. that L-captopril targets only the
Zn2+-metallo-isoform of the enzyme, whereas the Mn2+-enzyme was not inhibited. Since
the Mn2+-substituted isoform is also physiologically relevant in bacteria, it is important
while designating inhibitor compounds, as it has implications in substrate and ligand
binding at the active site in vivo.111 Even though L-captopril is a tight binding inhibitor of
DapE enzymes and is a promising lead compound for the development of a novel class of
DapE inhibitors, no information exists on how L-captopril binds to DapE, a requirement
for the rational design of new, more potent DapE inhibitors.
Evidence of L-captopril binding to the dinuclear active site of DapE was gleaned
from spectroscopic data obtained on the L-captopril complexes of the Co2+-substituted
forms for both HiDapE and NmDapE ([Co_(NmDapE)], [CoCo(NmDapE)],
[Co_(HiDapE)] and [CoCo(HiDapE)]). Electronic absorption spectra suggest that the
Co2+ ions bound to both HiDapE and NmDapE reside in either a distorted five- or sixcoordinate site.67b Upon the addition of L-captopril to either [CoCo(NmDapE)] or
[CoCo(HiDapE)], results in UV-Vis spectra where the λmax is red-shifted by ~30 nm
while the molar absorptivities increase by ~120 M-1cm-1 (Figure 19) The observed
changes upon L-captopril binding to the Co2+-forms of both NmDapE and HiDapE,
suggest that L-captopril interacts with both active site Co2+ ions.
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Interestingly, EPR spectra of [Co_(NmDapE)] and [Co_(HiDapE)] suggest the
Co2+ ion resides in a distorted tetrahedral coordination geometry at low temperature since
an MS =  3/2 signal persists between the temperatures of 4.5 and 13K, characterized by a
spike at g' ~ 6.5 (Figure 20).67b The fact that the presence of a feature at 13 K due to an
MS =  1/2 transition is almost completely extinguished at 4.5 K and high microwave
powers, renders the five- or six-coordination geometry highly unlikely and is explained
by thermal population of the MS =  1/2 Kramers’ doublet. EPR spectra of
[CoCo(NmDapE)] and [CoCo(HiDapE)] indicate a five- or six-coordinate Co2+ ion in the
second binding site due to the slow-relaxing ground state MS =  1/2 signal present at
both high and low temperatures and reveal substantial line-broadening at the low-field
line upon binding the second Co2+ ion, suggesting an increase of geometric flexibility
within the second Co2+ binding site.67b The EPR data also suggest an antiferromagnetic
interaction due to the formation if a spin-coupled species with |J| >> 0.3 cm-1 between the
Co2+ ions in [CoCo(HiDapE)].67b Some of the Co2+ appears to be EPR silent and the MS
=  3/2 signal is significantly diminished in [CoCo(HiDapE)] compared to
[Co_(HiDapE)] which is not the case for [CoCo(NmDapE)]. The addition of L-captopril
to [CoCo(NmDapE)] and [CoCo(HiDapE)] essentially extinguished the MS =  3/2 signal;
however, the other signals are unperturbed, indicating that the tetrahedral species has
gained a ligand (Figure 21). On the other hand, the addition of L-captopril to
[CoCo(HiDapE)] abolishes the EPR intensity suggesting that the spin-coupling between
the two Co2+ ions increases upon L-captopril binding indicative of a thiolate bridge
between the two active site Co2+ ions.
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Additional electronic information on [CoCo(NmDapE)] and [CoCo(HiDapE)] and
their L-captopril complexes was derived from MCD data (Figure 22). For both
[CoCo(NmDapE)] and [CoCo(HiDapE)] characteristic bands for high-spin Co2+ in a
distorted tetrahedral and distorted octahedral ligand field are observed, consistent with
EPR data. An interesting finding is that despite the similarity in the MCD spectra
between [CoCo(NmDapE)] and [CoCo(HiDapE)], the spectra obtained for
[CoCo(NmDapE)] reveals that both the four- and six-coordinate sites are occupied upon
the addition of only 1 eq. of Co2+ suggesting a cooperative binding model for NmDapE
that is not observed for HiDapE. This finding is consistent with EPR data as well as the
X-ray crystal structure of [Zn_(NmDapE)] where one of the active sites contains a Zn2+
ion bound in the first metal binding site while in the second active site contains two Zn2+
ions with occupancies modeled at 50% for Zn1 and 20% for Zn2. Correlation of the
observed ZFS with coordination number was used as a coordination number indicator
(referred to as the CN/ZFS correlation). In the CN/ZFS correlation, four-coordinate Co2+
exhibits ZFS < 13 cm-1, five-coordinate between 20 and 50 cm-1, and six-coordinate > 50
cm-1.112 The ZFS parameters determined from fits of VTVH data for [CoCoNmDapE]
and [CoCoHiDapE] are consistent with four-coordinate and six-coordinate Co2+ centers
in the active site. Based on previously published magnetic properties of several μ-aqua
μ-hydroxo dicobalt(II) model complexes, weak to moderately strong antiferromagnetic
coupling would be expected from a single oxygen atom bridge.113 Fitting of the VTVH
data from [CoCoNmDapE] and [CoCoHiDapE] strongly suggest that the bridging atom is
in the μ-aqua as opposed to a μ-hydroxo form.
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Upon the addition of L-captopril to [CoCoNmDapE] and [CoCoHiDapE] the
bands shift for both the four- and six-coordinate Co2+ ions and a decrease in the MCD
intensity is also observed (Figure 22). These data are consistent with the thiol of Lcaptopril bridging between the two active site Co2+ ions producing an
antiferromagnetically coupled dicobalt(II) center with an S = 0 ground-state. The overall
changes strongly suggest that the L-captopril displaces the bridging water molecule and
binds to both metals through a monatomic bridge that exhibits a lower ligand field
strength than that of water. These data are consistent with EPR data and also EXAFS
spectra for [CoCoHiDapE] bound by L-captopril. Upon binding L-captopril, the Zn-Zn
distance increases by 0.08 Å and a new feature at 2.3 Å appears that is highly
characteristic of a direct zinc-sulfur interaction. Taken together, these data indicate that
L-captopril interacts with both metal ions and strongly suggests the replacement of the
bridging water molecule with a more strongly bound ligand such as the thiol functionality
of L-captopril.
A major limitation in developing a previously undescribed class of antimicrobials
that target DapE enzymes is the lack of knowledge about inhibitor binding to the DapE
active site including potential residues involved in substrate recognition and binding.
While the spectroscopic studies suggest that L-captopril bridges between the two active
site metal ions in DapE in solution via a μ-thiolate moiety, these data provide no detailed
information regarding any interaction of the remaining functional groups of L-captopril
with the active site. In order to further characterize the binding of L-captopril to DapE,
the [ZnZn(NmDapE)] enzyme was crystallized in the presence of L-captopril and the X-

83
ray crystal structure was determined to 1.8 Å resolution (Figure 24). As predicted by the
EPR, MCD, and EXAFS data, no active site ligands are displaced upon L-captopril
binding except the water molecule that bridges the two Zn2+ ions in the wild-type
structure. This bridging water molecule is displaced by the thiol sulfur of L-captopril
with Zn1-S and Zn2-S distances 2.3 Å. L-captopril binding also increases the Zn-Zn
distance from 3.3 Å to 3.4 Å. The binding of L-captopril to the dinculear active site of
[ZnZn(NmDapE)] provides the first structural data for an inhibited form of any DapE
enzyme providing a model for inhibitor design as well as enzyme-substrate interactions.
DapE enzymes have strict specificity for the L,L-isoform of SDAP.67b This
specificity is built into the active site that includes both the dinuclear metal cluster as well
as adjacent amino acid residues that form a substrate binding pocket. Several studies
indicate that substrate binding pockets play an important role in substrate recognition and
binding for metallohydrolases.41a, 114 Inspection of the X-ray crystal structures of
[Zn_(NmDapE)] and [ZnZn(NmDapE)], combined with surface analysis, reveals a smileshaped cavity that extends along the catalytic domain and surrounds the active site. This
well-defined and negatively charged cavity is shaped from the top by strand 12 and 8
and in the middle by the loop connecting these two elements. The bottom of the cavity is
formed by a loop connecting -strands 6 and 7, and a loop connecting 5 and 4.
Taking into account the linear character of the substrate, it is likely that the substrate
binds in an extended conformation, lining up along the grove with the peptide bond
positioned over the active site metals. Insight into the role of this cavity comes from the
[ZnZn(NmDapE)]-L-captopril structure as several interactions between the inhibitor and
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residues within this cavity are formed. The O1 carbonyl oxygen of the L-captopril (the
carbonyl oxygen of the peptide bond) forms a hydrogen bond with a well-ordered water
molecule (2.8Å), which is stabilized by R179 (NH2-O; 3.1 Å) and P165 (2.6 Å). In
addition, the carboxy-end of the proline moiety of L-captopril is held in position by ionic
interactions between N346 (ND2-O3; 3.0 Å) and the amide of G325 (N-O2; 2.9 Å).
Interestingly, the carboxy group also forms a hydrogen bond with the hydroxyl moiety of
Y198 (OH-O3; 2.5 Å), which resides on the other subunit of the dimer. This interaction
is of great interest, since it is first evidence of a residue from the second subunit
interacting with an inhibitor bound to the first subunit. This suggests a heretofore
unknown function for the dimerization of DapE enzymes. These data suggest that the
dimerization domain is not only crucial for dimer formation but could also play an
important role in substrate recognition and binding of substrate. This is consistent with
dimerization domain deletion mutants of HiDapE, which were inactive highlighting the
importance of DapE dimer formation.37
In summary, we have spectroscopically and crystallographically characterized the
binding of L-captopril to DapE. The thiol moiety of L-captopril coordinates to both active
site metal ions in a μ-thiolate fashion. No other inhibitor centered ligands interact with the
active site metal ions. Since the X-ray crystal structure of the [ZnZn(NmDapE)]-Lcaptopril complex is the first structure of a DapE enzyme complexed by an exogenous
ligand, several active site pocket residues including R179, P165, and N346 were identified
that form hydrogen bonds to functional groups of L-captopril. Remarkably, the Y198
residue on subunit B was discovered to be involved in hydrogen bond formation with the
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L-captopril inhibitor bound to the active site in subunit A. This unforeseen hydrogen
bonding interaction may prove crucial in the development of novel medicinal chemistry
leads and may also be critical for catalysis. Since L-captopril is an angiotensin-converting
enzyme (ACE) inhibitor and a moderately strong inhibitor of DapE enzymes,
understanding the electronic and structural properties of L-captopril binding to the active
site of DapE provides a foundation for the design of new, more potent DapE inhibitors.

CHAPTER FOUR
DISCOVERY OF NOVEL DAPE INHIBITORS THROUGH HIGHTHROUGHPUT SCREENING
Introduction
Bacterial infections, some of which were thought to be eradicated, have made a
significant resurgence due to bacterial resistance to all known antibiotics.2, 4-5, 115
Resistance occurs because microorganisms that cause infections quickly develop ways to
survive drugs meant to kill or weaken them through random mutation and natural
selection. Once a mutated gene is generated, bacteria horizontally transfer this genetic
information by plasmid echange.4-5 Consequently, it's important to the health and general
welfare of society to continually renew our arsenal of compounds that combat these
pathogens.116 Ideally, such new compounds would target enzymes involved in bacterial
cell wall synthesis or pathways involved in cell replication.117 The dapE-encoded Nsuccinyl-L,L-diaminopimelic acid desuccinylase (DapE), a member of the mesodiaminopimelate (mDAP)/lysine biosynthetic pathway, is just such as candidate as a
novel target for the development of a new class of antibiotics. DapE’s catalyze the
hydrolysis of N-succinyl-L,L-diaminopimelic acid (SDAP) to diaminopimelate and
succincate (Figure 4), both of which are required for protein synthesis and peptidoglycan
layer formation in both Gram-positive and Gram-negative bacterial cell walls.59 Deletion
of the gene encoding for DapE, is lethal to H. pylori and M. smegmatis, even in the
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presence of lysine supplemented media.
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Therefore, DapEs are essential for cell growth

and proliferation. Since there are no similar biosynthetic pathways in mammals,
inhibitors that target DapEs are hypothesized to exhibit selective toxicity against
bacteria.27
DapE enzymes belong to the M28 family of dinuclear Zn(II)-dependent
metalloproteases all of which contain a (μ-aquo)(μ-carboxylato)dizinc(II) core with one
terminal carboxylate and one histidine residue at each metal site.62 The amino acid
residues that function as metal ligands in the crystallographically characterized DapE
enzymes are identical to other M28 family members, including the carboxypeptidase
from Pseudomonas sp strain-RS-16 (CPG2) and the leucine aminopeptidase from
Aeromonas proteolytica (AAP), which contain a terminal histidine and carboylate residue
at each site.28-29, 64a, 67b, 88b X-ray crystallographic and kinetic data obtained on the DapE
from Haemophilus influenzae (HiDapE) indicate that the divalent metal binding sites
bind in a sequential fashion and that the enzyme exhibits ~60% activity, based on kcat, in
the presence of one Zn(II) ion. These structural data provide the foundation for the
design and synthesis of novel molecules, representing different structural classes that
contain various zinc-binding groups (ZBGs). Typical ZBGs include thiols, carboxylic
acids, boronic acids, and phosphates. High-throughput screening (HTS) has been
successful in discovoring inhibitors for several metallohydrolases, including
metalloform-specific inhibitors (i.e. preferentially bind to mononuclear vs. dinuclear
forms of an enzyme). For example, metalloform-specific inhibitors has been identified
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using HTS for methionine aminopeptidases (MetAP), which bind one metal ion in vivo
and are active with a variety of divalent first row transition metal ion.118
Inhibitor screening via HTS of DapE enzymes has been limited by the lack of a
spectrophotometric assay that is amenable to HTS. To overcome this issue, we report
herein a reliable and reproducible spectrophotometric assay for DapE enzymes. Utilizing
this assay, we analyzed the binding ability of over 39,000 compounds representing
different structural classes and containing different ZBG’s. This approach identified five
novel inhibitors of DapE enzymes and these lead compounds, along with several
derivatives, were examined to determine their potential structure-activity relationships
(SARs).
Materials and Methods
Reagents. All chemicals used were purchased commercially and were of the
highest quality available. All metal reagents were obtained from Strem Chemicals,
Newburyport, MA with 99.999% purity. Stock solutions Zn(II) (10 mM) were prepared
by dissolving the metal chloride salts (ZnCl2) in nanopure water.
Expression and Purification of HiDapE. Plasmid containing the HiDapE gene
with an N-terminal His6-tag was transformed into BL21(DE3)/magic Escherichia coli
competent cells and grown in Luria-Bertani Broth as previously reported.119 The
following steps were performed at 4 ˚C. The DapE was purified according to the
standard protocol for Ni-NTA affinity chromatography, as described previously.91 The
His6-tag was removed by treating each enzyme with His6-tagged TEV protease for 16 h at
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4 ˚C in 50 mM HEPES, pH 8.0. Cleaved protein was separated from TEV using Ni-NTA
affinity chromatography.
Expression and purification of L,L-diaminopimelate aminotransferase (LL-DAPAT) from E. coli. The plasmid for LL-DAP-AT was kindly provided by Professor John
C. Vederas and LL-DAP-AT was expressed and purified following the published
procedure.120 Briefly, the plasmid was transformed into E. coli strain M15 (pREP4)
(Qiagen Inc.) and grown in 2×YT medium at 37 ˚C until an OD600 of 0.7 was reached
with shaking. IPTG was added (1 mM) and culture growth was continued for 4 h. Cells
were recovered by centrifugation (12,000g) for 15 min. at 4 ˚C using a Beckman Coulter
Avanti J-E Centrifuge. The resulting cell paste was suspended in lysis buffer (50 mM
sodium phosphate, 300 mM NaCl, 10 mM imidazole, 10 mM 2-mercaptoethanol (pH 7.7)
and lysed by sonication. Next, the protein was purified according to the standard
protocol for Ni-NTA affinity chromatography, as described previously.91 The column
was washed with lysis buffer and eluted using a gradient of 50 mM sodium phosphate,
300 mM NaCl, 200 mM imidazole, and 10 mM 2-mercaptoethanol (pH 8.0). The protein
was dialyzed against 200 mM NaCl, 20 mM HEPES- KOH (pH 7.6), 3 mM TCEP and
stored at -80 ˚C until further needed.
Enzyme-Coupled Spectrophotometric Assay. Testing was carried out using 96
well plates with a total volume of 218 μl in each well. Every well on the plate, except the
last row, contained 50 µL of compound (final conc 95 µM) in 1.25% DMSO. The last
row served as a negative control and contained only 1.25% DMSO. Second to last row
served as a positive control and contained enzyme completely inhibited by EDTA (30
mM). The reaction mixture containing DapE 0.15 µM, HEPES-KOH 100 mM (pH 7.6)
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was added to individual wells on the microplate and allowed to incubate for 10 min at 25
˚C. Next, 40 μl of the reaction mixture in HEPES-KOH (100 mM at pH 7.6) containing
DapE (0.25 µM), LL-DAP-AT (1µM), 2-OG (1 mM), OAB (10 mM) was added to
individual wells of the microplate using a 96-channel robotic liquid dispenser. The
reaction was then initiated by addition of 1.5 mM SDAP. The initial absorbance was
measured at 440 nm with a SpectraMax Plus384 microplate reader. The final absorbance
was measured after 3 h.
For the discontinuous assay, the reaction mixture containing DapE 0.15 µM,
HEPES-KOH 100 mM (pH 7.6) was added to individual wells on the microplate and
allowed to incubate for 10 min. at 25 ˚C. The reaction was initiated by addition of 3.6
mM SDAP and the reaction was allowed to proceed for 15 min. after which is was
stopped by addition of EDTA (30 mM) via the direct addition into the well and allowed
to incubate for 1 h. The second part of the reaction was introduced by addition of
HEPES-KOH 100 mM (pH 7.6), 2-OG (8.5 mM), OAB (10 mM), and LL-DAP-AT
(3µM) and the initial absorbance was measured at 440 nm with a Spectra94 microplate
reader and again after 3 h at the plateau region.
Controls on LL-DAP-AT were carried out in similar fashion using 96 well plates.
Every well on the plate, except the last row, contained 50 µL of compound (final conc 95
µM) in 1.25% DMSO. The last row served as a negative control and contained only
1.25% DMSO. The second to last row served as a positive control and contained no LLDAP-AT enzyme. Next, a reaction mixture containing HEPES-KOH 100 mM (pH 7.6),
2-OG (8.5 mM); OAB (7 mM); DAP (2.3 mM assuming 25% of total DAP) was
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aliquated to each well on a plate. The reaction was initiated by addition of LL-DAP-AT
(3µM) and the absorbance was monitored at 440 nm on a Spectra94 microplate reader.
High-Throughput Screening. High-throughput screening was carried out using
348 well plates with a total volume of 60 μl in each well. Every well on the plate, except
the last row, contained 20 µL of compound (final conc 12 µM) in 1.25% DMSO. The
last row served as a negative control and contained only 1.25% DMSO. The second to
last row served as a positive control and contained no DapE enzyme. Next, 40 μl of the
reaction mixture in HEPES-KOH (100 mM at pH 7.6) containing DapE (0.25 µM), LLDAP-AT (1µM), 2-OG (1 mM), OAB (10 mM) was added to individual wells of the
microplate using a 96-channel robotic liquid dispenser. The reaction was initiated by the
addition of 1.5 mM of SDAP and the initial absorbance measured at 440 nm with a
SpectraMax Plus384 microplate reader. The final absorbance was measured after 3 h.
Results and Discussion
The discovery of novel inhibitors of DapE enzymes has been hindered due to the
lack of a spectrophotometric assay that can continuously monitor, in real-time, a product
in the visible region.26 The current DapE kinetic assay monitors the decrease in
absorbance at 225 nm due to the hydrolysis of N-succinyl-L,L-diaminopimelic acid
(SDAP), forming L,L-diaminopimelic acid (DAP) and succinate (Figure 4).
Unfortunately, measurements performed at wavelengths in the UV region are subject to
significant interference from other biological components, inhibitor side-chains, and
compounds commonly used to make buffer solutions. Therefore, such an assay is not
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Figure 4. Reaction catalyzed by DapE.
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amenable to HTS. To overcome this issue, an enzyme-coupled continuous
spectrophotometric assay was developed for DapE in 100 mM HEPES-KOH at pH 7.6 in
the presence of 1.25% DMSO based on the production of the DapE product DAP. As
previously reported, DAP functions as a substrate for LL-diaminopimelate
aminotransferase (LL-DAP-AT) from Arabidopsis thaliana, which can utilize DAP as an
amino donor and 2-oxoglutarate (2-OG) as an amino acceptor, to produce
tetrahydrodipicolinate (THDP). Reaction of THDP with 2-aminobenzaldehyde (OAB)
produces dihydroquinazolium (DHQ), which strongly absorbs at 440 nm (Figure 25).121
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Figure 25. Schematic for the enzyme-coupled continuous spectrophotometric assay used
for high-throughput screening of DapE inhibitors.

Unfortunately, the molar absorptivity of DHQ is unknown given to its instability;
therefore, DapE activity can only be expressed in absorbance units (AU) for this assay.
In order to optimize this enzyme-coupled continuous spectrophotometric assay for HTS
experiments, several control reactions were carried out. In the absence of DapE, SDAP,
OAB, LL-DAP-AT, or 2-OG no increase in absorbance at 440 nm was observed. These
data indicate that the increase in absorbance observed at 440 nm is dependent on the
concentration of DapE, SDAP, and LL-DAP-AT verifying that the hydrolytic reaction
catalyzed by DapE is required for the production of DHQ. Titrations, in which the
concentrations of DapE, SDAP, and LL-DAP-AT were systematically varied, were
carried out by monitoring the absorbance at 440 nm in 100 mM HEPES-KOH at pH 7.6
in the presence of 1.25% DMSO (Figure 26). These titration data provided the optimum
concentrations of DapE, SDAP, and LL-DAP-AT to produce the maximum absorbance at
440 nm. Once these concentrations were optimized, the concentrations of 2-OG and
OAB were also systematically altered. Interestingly, at 2-OG concentrations greater than
1 mM, the observed absorbance at 440 nm decreased in 100 mM HEPES-KOH at pH 7.6
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Figure 26. Optimization of the enzyme coupled continuous spectrophotometric assay for
high-throughput screening of DapE. Varied concentration of DapE, L,L-SDAP, LLDAP-AT, OAB and 2-OG in 100 mM HEPES-KOH, pH 7.6 at 25 °C.
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in the presence of 1.25% DMSO (Figure 3B). No such decrease was observed for OAB.
This observed decrease in absorbance at 440 nm is likely due to product inhibition, since
2-OG could potentially mimic DAP at high concentrations, which is one of the products
of SDAP hydrolysis. Therefore, 1 mM 2-OG concentrations were used in all screenings
experiments. To further test the viability of the DapE enzyme-coupled continuous
spectrophotometric assay a known DapE inhibitor, L-captopril, was examined (Figure
27). L-captopril, an angiotensin-converting enzyme (ACE) inhibitor, inhibits the DapE
from H. influenzae with an IC50 value of 3.3 μM and a measured Ki of 1.8 μM
(competitive) 42 but does not inhibit LL-DAP-AT. By monitoring the formation of DHQ
at 440 nm in the presence of various concentrations of L-captopril in 100 mM HEPESKOH at pH 7.6 in the presence of 1.25% DMSO, a clear decrease in absorbance at 440
nm is observed as a function of L-captopril concentration. The enzyme-coupled
spectrophotometric assay can also be run in a discontinuous fashion. Quenching the
DapE reaction after 15 min with 30 mM EDTA followed by a 1 h incubation period after
which all other reagents in 100 mM HEPES-KOH at pH 7.6 are added, is adventitious to
remove any metal ions that might interfere with the activity of LL-DAP-AT by binding to
DAP. To test the discontinuous enzyme-coupled spectrophotometric assay, the DapE
inhibitors L-captopril and L-penicillamine were investigated at various concentrations
(Figure 28). As the amount of L-captopril or L-penicillamine increased, the absorbance
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Figure 27. DapE activity and inhibition of L-captopril monitored using an
enzymecoupled continuous spectrophotometric assay in 100 mM HEPES-KOH, pH 7.6 at
25 °C in the presence of varying concentrations of L-captopril: 0, 50, 100, 200 and 500
µM.
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Figure 28. The inhibition of DapE using an enzyme-coupled discontinuous
spectrophotometric assay in 100 mM HEPES-KOH, pH 7.6 at 25 °C in the presence of
varying concentrations of (A). L-captopril: 0, 15, 50, 100, 300 and 2000 µM; and (B). Lpenicillamine: 0, 300, 500, 1000 and 3000 µM.
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at 440 nm decreased proportionately. These data indicate that both the continuous and
discontinuous assays respond as expected towards the inhibition of DapE. Therefore, this
enzyme-coupled assay directly reflects the hydrolysis of SDAP by DapE.
While this enzyme-coupled continuous spectrophotometric assay for DapE
appears promising, a viable HTS assay must discriminate between actual inhibitors and
false positives. Therefore, prior to large-scale HTS studies, the Z’-factor, the most
commonly used parameter to describe the quality of an assay, was determined where a
single 384 well plate was analyzed to assess the quality of the assay, in order to warrant
whether the assay’s response is sufficient in comparison to control compounds. The Z’
value is defined by:
Z’ = 1 –_3(SDcontrol+ + SDcontrol-)_
|meancontrol+ - meancontrol-|

(eq. 1)

where SDcontrol+ and SDcontrol– represent standard deviations of the signals from positive
and negative controls, respectively, and meancontrol+ and meancontrol– represent the values
corresponding to the means.122 The Z-factor for the DapE enzyme-coupled continuous
spectrophotometric assay was found to be 0.89, indicating excellent separation between
positive and negative control samples.122 Therefore, this DapE assay is a viable
endpoint-type measurement mode, which allows for an increase in throughput without
sacrificing assay quality.
With a viable DapE assay in hand that is amenable to HTS, the hydrolysis of
SDAP was monitored by following the formation of DHQ at 440 nm in 100 mM HEPESKOH at pH 7.6 in the presence of 1.25% DMSO. At this point, 39,072 compounds have
been screened successfully using the HTS approach. This productive screen provided
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five clear hits that exhibit a >20% inhibition of DapE (Figure 29). Unfortunately,
inhibition studies were not viable for any of these five compounds due to their poor
solubility in buffered aqueous solution. Even so, four out of five compounds contained
either a sulfonamide or sulfonyl functional group and a carbonyl moiety three to four
atoms away. This structural backbone is of particular interest, as sulfonamides have
previously been shown to possess biological activity particularly as antibacterials,
diuretics, antidiabetics, antithyroid, antihypertensive, or antiviral agents.123 Sulfonamides

Figure 29. Compounds discovered via high-throughput screening.
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have also attracted attention recently as the amino group can function as a metal
ligand.124 Amines are commonly used as inhibitors of Zn(II) metalloproteins since Zn(II)
is a good Lewis acid and amines serve as good Lewis bases.110 Therefore, it was
hypothesized that compounds containing these groups might be involved in DapE
inhibition by coordination to the dinuclear Zn(II) active site. Since two out of the five
lead compounds contain idoline sulfonamides, a structure activity relationship (SAR)
study was undertaken based on this molecular backbone in order to identify structural
groups that are critical for DapE recognition and binding.
Several indoline sulfonamide derivatives were synthesized in collaboration with
Dr. Becker, where both X and R were varied (Figure 30). Each of these inhibitors was
screened using the DapE enzyme-coupled discontinuous spectrophotometric assay, and
the percent inhibition calculated:

% Inhibition = (Abs0- AbsI) x 100
Abs0

(eq. 2)

where Abs0 is the absorbance in the absence of inhibitor while AbsI is the absorbance in
the presence of inhibitor after a 3 h reaction period.
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Figure 30. Schematic for the idoline sulfonamides derivatives subjected to SAR studies.

Since sulfonamides have previously been shown to be LL-DAP-AT inhibitors, as
a control each inhibitor was also analyzed for inhibitory activity against LL-DAP-AT by
reaction with DAP in 100 mM HEPES-KOH at pH 7.6 and monitoring the formation of
DHQ at 440 nm.125 No inhibition towards LL-DAP-AT was observed for any of the
compounds tested. For comparison purposes, L-captopril inhibited 50% of the DapE
activity at a concentration of 100 µM while L-penicillamine inhibited 50% of the DapE
activity at a concentration of 500 µM. The best inhibitors tested were 1A, 2A, 3A and 5,
which exhibited 9.2% inhibition of the DapE hydrolysis reaction (Table 7).
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Table 7. Percent inhibition of derivative compounds of indoline sulfonamides (± 1.5% at
90 uM final concentrations)
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Each of these derivatives contains a bromo-indoline group with various hydrophobic R
groups such as piperidine, pyrrolidine cyclohexane or diethyl methoxy. Substituting the
R group with an isopropol (4A), aromatic ring (7A) or a bulkier dimethyl moiety (6A), or
alkyl carboxylic acid groups (8A, 9A, 10) decreases the inhibitory ability. Surprisingly,
the ability of 1A, 2A, 3A and 5 to inhibit DapE is not dependent on whether the
compound contains a secondary or tertiary amine adjacent to the sulfone functional
group. Therefore, the amine is unlikely serving as a ZBG, which may partially explain
the weak affinity for DapE of these compounds. Interestingly, simply substituting the X
group of the indoline sulfonamide backbone from bromo to chloro (1B, 2B, 3B)
decreases the inhibitory ability of the compounds by 30% to 83%. Clearly the size and
polarizability of this group is important for recognition and binding to DapE.
Shityakov et al. 126 recently published a study in which they emphasize the
importance of structure-activity relationship studies coupled with computational
techniques in order to analyze and confirm experimentally derived inhibitory data, since
this approach could be a valuable tool in the future design of potent medicinal lead
compounds. In the absence of structural information, SWISSDock was used to explore
potential binding modes and predict molecular interactions that may occur between DapE
and 1A.127 By analyzing the free energy of binding for multiple poses, the best binding
model was found where a sulfone oxygen atom bridges between the two Zn(II) ions with
the indoline carbonyl moiety binding to Zn2. An alternate pose was also explored where
the carbonyl oxygen from the indoline ring bridges between the two zinc ions and the
sulfone oxygen binds to Zn2 (Figure 8). While this would be a viable binding mode to
the dinuclear Zn(II) active site, the free energy of binding was significantly less negative.
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Figure 31. Docking pose for compound 1A. Color depiction: Blue: positive charge; Red:
negative charge.

Active site
cleft

Zn1 Zn2

Interestingly, the carbonyl oxygen atom is bound to only Zn2 while the pyrrolidine ring is
buried deeper into a hydrophobic pocket within the active site cleft. This binding mode is
favorable for inhibitors with less bulky, hydrophobic R groups. This binding pose is
consistent with SAR data in that potential inhibitors with bulky, or hydrophilic R groups
such as 4A, 6A, 7A, 8A, 9A, or 10 either do not inhibit DapE or are significantly weaker
inhibitors than 1A. It is evident from the docking simulations that the compounds with
the best inhibitory properties interact with the active site Zn(II) ions as well as active site
residues within a smile-shaped cleft that extends along the catalytic domain and
surrounds the active site (Figure 31). Therefore, linear structures without large, bulky
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groups and with a ZBG, such as the sulfone and/or carbonyl oxygen, would likely bind
the best to DapE. Such an inhibitor would also have to contain functional groups that are
properly positioned to form hydrogen bonds with active site lysine and arginine groups,
such as K135, R258, and R329 that reside in the smile-shaped cleft.
In conclusion, a rapid and reliable enzyme-coupled spectrophotometric assay for
DapE has been developed and tested against the previously reported DapE inhibitors Lcaptopril and L-penicillamine. This enzyme-coupled spectrophotometric assay allowed
for HTS studies to be conducted with over 39,000 compounds screened thus far providing
five new compounds that showed >20% inhibition, providing strong verification that the
newly developed coupled assay for DapE is selective and robust. Four of the five newly
identified DapE inhibitors contained a sulfone with two of the five containing an
excellent building block, an indoline sulfonamide. Eighteen new compounds were
synthesized and the resulting SAR analysis indicated the importance of the sulfone,
indoline carbonyl and bromo moieties along with a relatively small, hydrophobic group.
Inhibitor docking studies reaffirm the importance of each of these groups and propose a
µ-sulfone oxygen-binding mode with a terminal carbonyl oxygen atom. These new
medicinal chemistry lead compounds provide insight into the structural determinants of
inhibitor binding to the active site of DapE and how active site residues can be
advantageously targeted to improve inhibitor binding free energy. Given that multidrugresistant organisms pose a serious and increasing threat to human health, it is critically
important that new antibiotic lead compounds that target enzymes, such as DapE be
discovered.

CHAPTER FIVE
CONCLUSION
The overall goal of this research was to obtain valuable information on the
catalytic mechanism of DapE enzymes that might ultimately contribute in subjugating the
problem of increasing resistance of bacteria. The importance of this project is
emphasized by the emergence of bacteria that are resistant to some or all currently
available antibiotics. This trend of increasing resistance in bacteria makes today’s
antibiotics more and more ineffective, thus increasing the need for a new class of
antibiotics. One of the approaches to prevent this problem from getting out of control is
developing drugs that target essential bacterial biosynthetic pathways. Advances in the
area of genomics have influenced the discovery of novel antimicrobial agents greatly. It
has provided the ability to scientists to identify essential genes that result in the inhibition
of cell growth. This approach has been very useful in selecting the meso‐
diaminopimelate (mDAP)/lysine biosynthetic pathway, which identifies DapE as a
potential target for the development of antimicrobial agents.26
In order to accomplish the research objectives in this thesis and gain insight into
the catalytic mechanism of DapE along with the determinants of substrate/inhibitor
binding, several biochemical and biophysical techniques were employed. These data
have provided essential information for rational design of DapE inhibitors, which relies
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on understanding of the active site architecture including residues in and around the
active site that are important for substrate recognition and binding.
In Chapter 1, the significance of increasing antimicrobial resistance is presented.
Despite the critical need for new antibiotics to treat drug-resistant infections the number
of new antibiotics approved by the FDA has been declining significantly in the past two
decades with only five new antibiotics approved in the last few years.17 Fortunately,
congress together with other health organizations have recognized this growing problem
and raised awareness to the urgent need to develop new classes of antibiotics.
Policymakers have offered patent extensions as well as various tax breaks, in order to
revive interest and make antibiotic research profitable for pharmaceutical companies.
One example of this approach is the “10 x `20” initiative, which calls for U.S. and
European Union leaders to join forces and develop 10 novel antibiotics by 2020.21 This
is just one of the examples that our government is undertaking to try and restore interest
in antibiotic research. Another to approach this problem is to develop drugs that target
enzymes, such as DapE, that are present within essential bacterial biosynthetic pathways.
This approach should yield inhibitors that may exhibit selective toxicity against bacteria
and not humans, since there are no similar biosynthetic pathways in mammals.27 This
research should contribute to benefit the health and general wellbeing of society given
that multidrug resistant bacteria pose a serious and increasing threat to human health.
In Chapter 2, I examined the role of the catalytic domain of DapE by preparing
truncated DapE enzymes by deleting the dimerization domains of the DapE from Vibrio
cholera and H. influenzae (HiDapET and VcDapET). The resulting truncated enzymes,
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HiDapE and VcDapE , were hypothesized to be very similar to the aminopeptidase from
T

T

Aeromonas proteolytica (AAP), which is a monomeric protein and contains a single
catalytic domain.88b Interstingly, these studies revealed that removal of the dimerization
domain in DapE renders the enzyme inactive. The lack of activity was quite surprising
taking into the account that the mutants were folded properly and the overall structure
was very similar to WT DapE. Therefore, the truncated mutants were examined using
molecular dynamic, X-ray crystallographic, and mutagenesis methods to understand why
they were inactive. Analysis of the X-ray crystal structures of HiDapET and VcDapET
revealed that loop V is much more flexible in the truncated enzymes than WT-DapE due
to the lack of interactions provided by the dimerization domain. These data suggest that
the dimerization domain restricts the conformational freedom of the loop V region and
may contribute residues to the active site environment that are important for substrate
recognition and binding. Molecular Dynamic simulations, which were consistent with
the crystallographic data, showed that the truncated proteins have greater flexibility in the
loop created to replace the dimerization domain and also in the active site loop V.
Mutation of T325, a residue that resides on loop V and is positioned directly above the
dinuclear active site forming a hydrogen bond with the bridging water molecule,
confirmed that the position of loop V is important for the proper organization of active
site residues, which are directly to catalysis.119 Moreover, these data suggested that
designing small molecules inhibitors that interact with this active site loop V region as
well as the dinuclear metal center might lead to potent DapE inhibitors that can function
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as antibacterial agents. Disrupting dimer formation may also be an avenue to explore for
the development of potent DapE inhibitors.
In Chapter 3, I investigated the inhibition of L-captopril on the DapE enzymes
from H. influenzae and N. meningitidis. Previous studies have shown that L-captopril is a
competitive inhibitor of the DapE from H. influenzae (Ki = 3.3µM).42 L-captopril was
found to also be a competitive inhibitor of the DapE form N. meningitidis (Ki = 2.8 μM).
The electronic properties of the Co(II)-forms of DapE bound by L-captopril was
examined using electronic absorption, EPR, and MCD spectroscopies. In the presence of
L-captopril, UV-Vis spectra of Co(II)-substituted DapE enzymes revealed a red-shift in
the λmax of ~30 nm along with an increase in molar absorptivity, suggesting that Lcaptopril interacts with both metal ions in the dinuclear active site. EPR and MCD data
indicate that the Co(II) ions in [Co_DapE] and [CoCoDapE] are five- and six-coordinate,
respectively and are weakly antiferromagnetically coupled upon the addition of Lcaptopril yielding an S = 0 ground state. These data confirm that L-captopril interacts
with both metal ions residing within the active site of DapE and suggest that the thiolate
of L-captopril bridges between the two metal ions. Conformation of this proposed
structure was derived from EXAFS and X-ray crystallography. EXAFS data clearly
indicate the coordination of a thiolate to the dinuclear Zn(II) center of DapE with an
increase in the Zn-Zn distance, suggesting a bridging thiolate. The three-dimensional
structure of the DapE from N. meningitidis bound by L-captopril was solved to 1.78 Å.
This is the first structure of any DapE enzyme bound by an exogenous molecule. The
structure reveals that the thiolate of L-captopril does, in fact, bridge between the two
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Zn(II) ions consistent with the EPR, MCD, and EXAFS data. The results obtained in this
study provide new insight into the important determinants of inhibitor binding including
active site residues that form hydrogen-bonding interactions. These data are crucial for
the rational design and synthesis of potent DapE inhibitors.
In Chapter 4, new medicinal chemistry lead compounds for DapE enzymes were
discovered through high-throughput screening (HTS) studies. In order to perform HTS,
an enzyme-coupled continuous spectrophotometric assay for DapE was designed and
developed. The hydrolysis of N-succinyl-L,L-diaminopimelic acid (SDAP) was coupled
to L,L-diaminopimelate aminotransferase (LL-DAP-AT), which can utilize DAP as an
amino donor and 2-oxoglutarate (2-OG) as an amino acceptor, to produce
tetrahydrodipicolinate (THDP) that when coupled with 2-aminobenzaldehyde (OAB)
produces dihydroquinazolium (DHQ), which absorbs at 440 nm. Extensive testing of this
assay proved that it was dependent on the hydrolysis reaction catalyzed by DapE. With a
viable spectrophotometric assay in hand for DapE, HTS was carried out at the Chemical
Genomics Core Facility at Indiana University School of Medicine in collaboration with
Professor Ye. More than 39,000 compounds were screened with five inhibiting DapE
activity by >20 %, which is a strong verification that the newly developed coupled assay
for DapE is selective and robust. Four of these compounds contained either sulfonamide
or sulfonyl functional groups, which have not been explored previously as DapE
inhibitors. A discontinuous form of this enzyme-coupled assay was also developed to
test the inhibition of eighteen newly synthesized sulfonamide derivatives by determining
the percent inhibition. Four of the newly synthesized compounds proved to be moderate
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inhibitors of DapE. Finally, the best inhibitor was docked into the active site to analyze
the important inhibitor-enzyme interactions for the design of new, more potent DapE
inhibitors.
The completion of this research provided insight into the determinants of
substrate/inhibitor binding to DapE. In addition, new medicinal chemistry lead
compounds were discovered and studies were conducted to gains an understanding of
their mode of binding to DapE. These data are critical to future studies on the design and
synthesis of highly‐selective inhibitors of DapE. The discovery of such inhibitors will
potentially provide a novel class of antibiotics, which are desperately needed to fight the
spread of infectious disease.
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